Hematologic disorder
MONDO:0005570A disease involving the hematopoietic system.
Also known as: blood disease, blood disorder, disease of hematopoietic system, disease of the blood and blood-forming organs, disease or disorder of haematopoietic system, disease or disorder of hematopoietic system, disorder of haematopoietic system, disorder of hematopoietic system
7573 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1407 trials in this tab.
-
Can a short drug course end malaria relapses for good?
⭐️ CURE ⭐️ CompletedThis study tested how well the drug primaquine prevents the return of P. vivax malaria in 160 adults. Participants had uncomplicated malaria and normal G6PD levels. The goal was to see if a short treatment could stop relapses, aiming for a complete cure.
Phase: PHASE4 • Sponsor: University of Maryland, Baltimore • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
Double vaccine attack on malaria shows promise in early trial
⭐️ VACCINE ⭐️ CompletedThis study tested two different malaria vaccines—one targeting the blood stage and one the liver stage—alone and in combination. 107 healthy adults and infants in The Gambia received the vaccines to check safety and immune response. The goal is to see if combining them offers bet…
Phase: PHASE1 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:31 UTC
-
New malaria vaccines show promise in protecting indonesian soldiers
⭐️ VACCINE ⭐️ CompletedThis study tested two experimental malaria vaccines in 345 healthy Indonesian soldiers deployed to a malaria-endemic region. One vaccine uses weakened malaria parasites, and the other uses live parasites with a preventive drug. The goal was to see if either vaccine could safely p…
Phase: PHASE2 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Cancer drug Imatinib's Long-Term safety tracked in ongoing patients
Disease control CompletedThis study looks at the long-term safety of imatinib, a daily pill for certain cancers like GIST and CML. It includes 250 patients who were already benefiting from imatinib in a previous Novartis trial and continue taking it. The main goal is to track side effects over time, with…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immune cells supercharged to fight cancer: early trial shows promise
Disease control CompletedThis early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Weekly shot aims to get severe hemophilia patients moving more
Disease control CompletedThis study is testing a new medicine called efanesoctocog alfa in about 90 people aged 12 and older with severe hemophilia A. Participants receive a weekly injection for 24 months to see if it helps them be more physically active and improves joint health. The study uses activity…
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for young hemophilia patients: jivi safety trial shows promise for fewer injections
Disease control CompletedThis study tested the safety of Jivi (BAY 94-9027), a longer-lasting clotting factor, in 36 children aged 7 to 12 with severe hemophilia A. The medicine is already approved for older patients, but this trial focused on younger kids to check for allergic reactions and whether the …
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered donor cells take aim at returning blood cancers
Disease control CompletedThis early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill targets Hard-to-Treat lymphoma in early human test
Disease control CompletedThis early-stage trial tests an experimental oral drug called DZD8586 in adults with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to standard treatments. The study aims to find a safe dose and check whether the drug can shrink tumors. Participants take the …
Phase: PHASE1 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New program aims to keep patients on track after Infection-Related hospitalizations
Disease control CompletedThis study tested a program to help people with opioid use disorder stay on their medication after being hospitalized for serious infections like endocarditis or bone infections. Forty adults took part to see if the program was practical and helpful. The goal is to improve long-t…
Phase: NA • Sponsor: Boston Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug AZD9829 targets hard-to-treat blood cancers in early trial
Disease control CompletedThis study tests a new drug, AZD9829, in people with blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD123 found on cancer cells. The main goals are to find a safe dose and check for side effects. About 56 adults will take…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to prior therapies. It combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and standard chemotherapy. The main goal is to…
Phase: PHASE1 • Sponsor: Elvira Umyarova • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
One infusion could beat daily pills for Post-Birth anemia
Disease control CompletedThis study tests whether a single intravenous (IV) dose of iron works better than daily oral iron pills to treat moderate anemia in new mothers. About 4,800 women who have moderate anemia 6 to 48 hours after delivery will receive either a one-time IV iron infusion plus folic acid…
Phase: PHASE3 • Sponsor: NICHD Global Network for Women's and Children's Health • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cuts chemotherapy side effect by over 60% in breast cancer patients
Disease control CompletedThis study tested whether Naderin, an immune-boosting drug, could prevent low white blood cell counts in 79 women with breast cancer receiving first-line chemotherapy. Participants either received Naderin alongside chemotherapy or chemotherapy alone. The results showed that only …
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for rare blood disorder: experimental pill reduces need for transfusions
Disease control CompletedThis study tested a drug called bitopertin in 15 adults with Diamond-Blackfan anemia (DBA), a rare inherited condition that causes severe anemia. Participants took the pill daily for 8 months, with doses possibly increasing over time. The goal was to see if the drug could raise h…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
IV iron may beat pills for anemia in late pregnancy
Disease control CompletedThis study tests whether a single intravenous dose of ferumoxytol raises hemoglobin more effectively than daily oral ferrous sulfate in pregnant women with iron deficiency anemia. Participants are between 24 and 34 weeks pregnant with a single baby. The trial measures hemoglobin …
Phase: PHASE3 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental drug ANX005 targets blood cell destruction in autoimmune anemia
Disease control CompletedThis phase 2 trial investigates ANX005, an investigational drug given intravenously, for people with warm autoimmune hemolytic anemia (wAIHA). The study aims to assess the safety and tolerability of repeated doses, and to measure changes in blood markers like hemoglobin and bilir…
Phase: PHASE2 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Off-the-Shelf immune cells take on tough lymphoma
Disease control CompletedThis early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…
Phase: PHASE1 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug naderin may help patients fight infections during cancer and TB therapy
Disease control CompletedThis study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for frail AML patients: stronger chemo regimens tested
Disease control CompletedThis study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can help medically less-fit adults with acute myeloid leukemia live longer and achieve remission. About 60 participants will receive one of the two treatments. The goal is t…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
HIV-Fighting cells show promise in lymphoma treatment
Disease control CompletedThis study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…
Phase: PHASE2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a month of iron before knee or hip surgery cut transfusion risk?
Disease control CompletedThis trial investigates whether anemic patients scheduled for hip or knee replacement surgery benefit from taking an iron supplement (Sideremil Vita) for 30 days before the operation, compared to taking it for only 15 days. The goal is to see if the longer treatment reduces the n…
Phase: NA • Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug targets genetic weakness in Hard-to-Treat blood cancers
Disease control CompletedThis study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …
Phase: PHASE1, PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers in japanese patients
Disease control CompletedThis study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers (like leukemia and lymphoma). The goal is to see if it is safe and helps control the cancer. Participants take the drug daily, and researchers monitor side effects and how well the …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy blinatumomab shows promise in kids with relapsed leukemia
Disease control CompletedThis Phase 3 trial tested the drug blinatumomab in 111 children with high-risk relapsed B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is an immunotherapy that helps the body's immune cells attack cancer cells. The study compared blinatumomab to standard chemotherap…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Home infusion for myeloma drug passes early safety check
Disease control CompletedThis pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…
Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Cancer vaccine trial tests immune system boost for rare lymphoma
Disease control CompletedThis phase 1 trial tested a personalized DNA vaccine in 9 patients with a rare, slow-growing blood cancer called lymphoplasmacytic lymphoma. The vaccine was made from each patient's own cancer cells and designed to help the immune system recognize and attack the cancer. The main …
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a pill keep AML at bay? new study tests maintenance therapy after chemo
Disease control CompletedThis study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Rare disease drug shows promise in reducing infections
Disease control CompletedThis study tested two drugs, plerixafor and G-CSF, in 20 people with WHIM syndrome, a rare genetic condition that causes frequent infections and warts. Participants received each drug for a year and tracked their infections. The goal was to see which drug better reduced infection…
Phase: PHASE2, PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo aims to wipe out hidden myeloma cells after transplant
Disease control CompletedThis phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide maintenance therapy can clear remaining cancer cells in people with multiple myeloma who still have minimal residual disease after a stem cell transplant. About 200 participant…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control CompletedThis study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured h…
Phase: PHASE1, PHASE2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
Disease control CompletedThis large phase 3 trial studied nearly 1,900 children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Researchers compared different chemotherapy combinations, including varying doses of methotrexate and adding the drug…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug strategy may reduce blood transfusions after organ transplants
Disease control CompletedThis study looked at whether giving romiplostim, a drug that boosts platelet production, could reduce the need for platelet transfusions in patients with low platelet counts after heart or lung transplantation or use of heart/lung support devices. Researchers compared a group of …
Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise for Tough-to-Treat leukemia in seniors
Disease control CompletedThis study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell …
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Joint injection shows promise for stopping repeat bleeds in hemophilia
Disease control CompletedThis study tested whether injecting bevacizumab (a drug that blocks blood vessel growth) into the joints of people with hemophilia can prevent repeated bleeding episodes. Eighteen participants with chronic synovitis (joint inflammation) received the injection. Researchers measure…
Phase: NA • Sponsor: Khyber Medical University Peshawar • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Hormone drug may slow Aging-Related diseases in rare condition
Disease control CompletedThis study tested whether low doses of the hormone drug danazol can slow the shortening of telomeres—the protective caps on DNA—in people with telomere diseases. These conditions can cause bone marrow failure, lung scarring, and liver damage. Eighteen participants took danazol fo…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for returning bone marrow cancer
Disease control CompletedThis study tested a drug called ixazomib, alone or with other medicines, in 165 people whose multiple myeloma (a blood cancer) had come back. The goal was to see if these combinations could shrink or control the cancer. Participants received different treatment plans, and doctors…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis study tested a combination of two drugs, brentuximab vedotin and bendamustine, in 65 patients with Hodgkin lymphoma or anaplastic large cell lymphoma that had come back or didn't respond to earlier treatments. The goal was to find the safest dose and see how well the drugs w…
Phase: PHASE1, PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted therapy combo aims to improve survival in older leukemia patients
Disease control CompletedThis study tests whether adding the targeted drug inotuzumab ozogamicin to a milder chemotherapy regimen improves survival in adults over 55 with a specific type of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-negative and CD22-positive. Participants receive…
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma in major trial
Disease control CompletedThis phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered stem cells aim to speed recovery in blood cancer patients
Disease control CompletedThis trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard tra…
Phase: PHASE3 • Sponsor: Gamida Cell ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for stem cell transplant patients with dangerous blood clotting disorder
Disease control CompletedThis study tested a drug called ravulizumab in people aged 12 and older who developed a serious blood clotting condition (thrombotic microangiopathy) after a stem cell transplant. The goal was to see if the drug could prevent death or worsening of the condition over 26 weeks. Par…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Triple-Drug cocktail aims to boost remission in acute myeloid leukemia
Disease control CompletedThis phase 3 trial is testing whether a combination of three drugs—azacitidine, venetoclax, and ATRA—can safely and effectively treat adults newly diagnosed with acute myeloid leukemia (AML). The drugs work together to stop cancer cell growth by demethylating DNA, promoting cell …
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental pill targets Hard-to-Treat blood cancers
Disease control CompletedThis study tested a daily pill called E7820 in 12 adults with relapsed or treatment-resistant acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia. All participants had specific mutations in splicing factor genes. The goal was to see if the drug c…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill shows promise for sickle cell sufferers
Disease control CompletedThis study tested a new oral medicine called NDec in 96 adults with sickle cell disease. The goal was to see if it safely raises hemoglobin levels and reduces painful crises. Participants took capsules twice weekly for about a year, with some also continuing their usual hydroxyur…
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to deepen remission in multiple myeloma
Disease control CompletedThis phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat int…
Phase: PHASE2 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug could reduce need for plasma exchange in rare blood disorder
Disease control CompletedThis study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no pl…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Drug cocktail may cut transfusions for kids with thalassemia
Disease control CompletedThis study tested whether giving children with transfusion-dependent thalassemia a combination of hydroxyurea and thalidomide works better than either drug alone. Ninety children aged 3-18 were split into three groups: one getting both drugs, one getting only hydroxyurea, and one…
Phase: PHASE4 • Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Short-Course malaria treatment could prevent relapses
Disease control CompletedThis study tested a new approach to treat vivax malaria, a type that can hide in the liver and come back. Researchers used a quick test to check for a genetic condition (G6PD deficiency) that can cause dangerous side effects with the standard drug primaquine. Then, they gave a hi…
Phase: NA • Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple supplement ease sickle cell symptoms?
Disease control CompletedThis study tested a nutraceutical supplement called NUV001 in 168 adults with sickle cell disease. Participants took either an immediate-release or gastro-resistant version of NUV001, or a placebo, daily for 90 days. The main goal was to check safety and tolerability, with early …
Phase: NA • Sponsor: LGD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Herbal ointment shows promise for eczema relief
Disease control CompletedThis completed trial tested a herbal ointment made from Syzygium formosum leaves in 90 people with mild to moderate atopic dermatitis (eczema). The ointment was compared to standard moisturizers to see if it was safe and effective. The study measured skin severity, water loss, an…
Phase: NA • Sponsor: VinUniversity • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Local foods may help kids with sickle cell disease avoid malnutrition
Disease control CompletedThis study looked at whether teaching mothers about nutritious local foods can prevent malnutrition in children with sickle cell disease (SCD) in northern Nigeria. 146 children aged 6 to 18 months with SCD took part. Community health workers gave mothers special nutrition advice,…
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug RAD001 tested for tough leukemias and lymphomas
Disease control CompletedThis study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a bone drug stop smoldering myeloma in its tracks?
Disease control CompletedThis study looked at whether denosumab, a drug usually used for bone health, could safely reduce the risk of smoldering multiple myeloma turning into active multiple myeloma. Twenty people with smoldering multiple myeloma took part. The goal was to see if the drug could lower the…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows early promise for recurrent lymphoma
Disease control CompletedThis early-phase trial tested two drugs, lenalidomide and idelalisib, in 8 people with follicular lymphoma that had returned after previous treatment. Lenalidomide helps the immune system fight cancer, while idelalisib blocks enzymes that cancer cells need to grow. The main goal …
Phase: PHASE1 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for leukemia patients
Disease control CompletedThis early-phase study tested a combination of two drugs, daratumumab and ibrutinib, in 15 people with untreated chronic lymphocytic leukemia (CLL) who needed therapy. The goal was to see if the combination is safe and how well it works at controlling the disease. Participants re…
Phase: PHASE1 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells show promise against Hard-to-Treat lymphoma
Disease control CompletedThis study tested a treatment called tisagenlecleucel, a type of CAR-T cell therapy, in 98 adults with follicular lymphoma that had come back or stopped responding to other treatments. The therapy works by reprogramming a patient's own immune cells to find and attack cancer cells…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Iron therapy showdown: daily vs. Alternate-Day for anemic kids
Disease control CompletedThis study tested whether giving oral iron every other day works as well as daily dosing for treating iron deficiency anemia in children up to 5 years old. Sixty children participated, and researchers measured changes in hemoglobin and ferritin levels. The goal was to find a simp…
Phase: PHASE3 • Sponsor: University of Child Health Sciences and Children's Hospital, Lahore • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Iron shot beats pills for new Moms' anemia?
Disease control CompletedThis study tested whether an iron injection works better than iron pills for treating anemia in 200 new mothers within 10 days of giving birth. Participants had mild to moderate anemia and were randomly assigned to receive either a single injection of ferric carboxymaltose or ora…
Phase: PHASE2, PHASE3 • Sponsor: ESI-PGIMSR, Basaidarapur • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo shows promise for Tough-to-Treat blood cancer
Disease control CompletedThis study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New sickle cell drug candidate enters first human tests
Disease control CompletedThis early-stage trial tested a new drug called PF-07209326 in 52 people, first in healthy volunteers and then in patients with sickle cell disease. The main goal was to check safety and how the body processes the drug. Researchers also looked for any early signs that the drug mi…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Treadmill training boosts fitness in anemic women
Disease control CompletedThis study tested whether adding a structured treadmill walking program to standard iron therapy improves exercise tolerance and quality of life in young women with mild-to-moderate iron deficiency anemia. Sixty women aged 18-28 were split into two groups: one received iron suppl…
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancer
Disease control CompletedThis early-phase trial tested a new gene therapy for multiple myeloma, a blood cancer that often becomes resistant to standard treatments. Researchers took participants' own immune T cells, modified them in the lab to recognize a protein called BCMA on myeloma cells, and infused …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may shield cancer Patients' hearts from chemo damage
Disease control CompletedThis study looked at whether using a blood test (NTproBNP) to guide heart-protecting medications can safely prevent heart damage in people with breast cancer or lymphoma receiving anthracycline chemotherapy. About 108 adults participated, and researchers measured how many joined,…
Phase: PHASE1, PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested whether adding idelalisib to lenalidomide helps people with mantle cell lymphoma that has returned or is resistant to treatment. Lenalidomide boosts the immune system to fight cancer, while idelalisib blocks enzymes that help cancer cells grow. The trial involve…
Phase: PHASE1 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data suggests asciminib may help some leukemia patients
Disease control CompletedThis study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within th…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for elderly lymphoma patients: a gentler treatment that preserves independence
Disease control CompletedThis phase 2 trial investigates whether combining rituximab with lenalidomide works as well as standard rituximab-based chemotherapy for patients aged 75 and older with relapsed diffuse large B-cell lymphoma. The study focuses not only on controlling the cancer but also on mainta…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody shot shows promise against malaria in early trial
Disease control CompletedThis early-stage trial tested a lab-made antibody called MAM01 in 63 healthy adults who had never had malaria. The goal was to see if it is safe and can prevent malaria infection when people are deliberately exposed to the parasite. The study is complete, but results are not yet …
Phase: PHASE1 • Sponsor: Gates Medical Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug doses tested for rare blood cancer
Disease control CompletedThis phase 2 trial tested two different daily doses of the drug orelabrutinib in 40 people with mantle cell lymphoma, a rare blood cancer. The goal was to see which dose works better at shrinking tumors and controlling the disease. Participants included both newly diagnosed and r…
Phase: PHASE2 • Sponsor: InnoCare Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody combo aims to tackle Hard-to-Treat multiple myeloma
Disease control CompletedThis trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New oxygen test could cut unnecessary blood transfusions after heart surgery
Disease control CompletedThis study tested whether measuring oxygen levels in the blood (ScvO2) can help doctors decide when to give blood transfusions to anemic patients after heart surgery. 100 patients were randomly assigned to receive transfusions based on standard guidelines or only if their ScvO2 w…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
Disease control CompletedThis phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…
Phase: PHASE2 • Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR-T therapy takes on standard care in lymphoma battle
Disease control CompletedThis Phase 3 trial tested whether the CAR-T cell therapy tisagenlecleucel works better than standard treatments for adults with aggressive B-cell non-Hodgkin lymphoma that came back or didn't respond to initial therapy. The study enrolled 330 participants and compared how long th…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise for rare blood cancer in Late-Stage trial
Disease control CompletedThis phase 3 study tested an oral drug called azacitidine (CC-486) against standard treatments in 93 adults with a rare T-cell lymphoma that had relapsed or stopped responding. The main goal was to see if the drug could delay cancer progression or death. Participants were randoml…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Chemotherapy-Free combo aims to boost remission in younger AML patients
Disease control CompletedThis phase 2 trial is testing whether a combination of two drugs, venetoclax and azacitidine, can effectively treat adults aged 18 to 59 who have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received any treatment. Participants take both drugs in cycles…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to tackle rare blood cancer
Disease control CompletedThis phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can a pill keep mantle cell lymphoma away? new study tests ibrutinib maintenance
Disease control CompletedThis study tested whether the drug ibrutinib can safely keep mantle cell lymphoma from returning after initial chemotherapy. Thirty-seven patients who had already responded to chemo took ibrutinib as a maintenance therapy. Researchers tracked how long patients stayed cancer-free …
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a common blood pressure drug help heal hearts in sickle cell disease?
Disease control CompletedThis study tested whether losartan, a blood pressure medication, can reduce or stop scarring in the heart muscle of people with sickle cell disease. Fourteen participants aged 6 and older took losartan for 12 months. The goal was to see if the drug could improve heart health and …
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New toothpaste fights gum disease in 12-Week trial
Disease control CompletedThis study tested whether a stannous fluoride toothpaste can reduce gum inflammation, bleeding, and plaque better than a standard fluoride toothpaste. Over 12 weeks, 133 adults brushed with one of the two toothpastes and had their gums checked at several visits. The goal was to s…
Phase: NA • Sponsor: Church & Dwight Company, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for rare blood cancers: fedratinib shows promise in early trial
Disease control CompletedThis study tested a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal was to see if the drug could shrink the spleen and improve blood counts. While not a cure, the treatment aims to control the disease and reduce symptoms.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a shot keep smoldering myeloma from igniting?
Disease control CompletedThis phase 3 study tested whether the drug daratumumab, given as a shot under the skin, could delay or prevent smoldering multiple myeloma from turning into active multiple myeloma. 390 people with high-risk smoldering myeloma were randomly assigned to receive daratumumab or to b…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for tough lymphoma: experimental drug shows promise
Disease control CompletedThis study tested an experimental drug called ICP-022 in 106 adults with mantle cell lymphoma that had come back or stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check its safety. The approach focuses on controlling the disease…
Phase: PHASE1, PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo shows promise for tough leukemia cases
Disease control CompletedThis phase 2 trial tested a combination of two drugs, ibrutinib and blinatumomab, in 19 adults with B-cell acute lymphoblastic leukemia that had come back or wasn't responding to treatment. The goal was to see how many patients achieved complete remission. The study is completed,…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for leukemia patients: asciminib shows promise in indian study
Disease control CompletedThis study looked at the safety and effectiveness of a drug called asciminib in 85 Indian adults with a specific type of leukemia (Ph+ CML-CP). Some participants had a genetic mutation (T315I) that can make treatment harder, while others had already tried two or more other drugs.…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered immune cells target tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new treatment for children and young adults with a type of leukemia that came back or did not respond to standard therapy. The approach uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein c…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy shows promise for hard-to-treat leukemia
Disease control CompletedThis early-phase trial tested whether adding the drug uproleselan to standard chemotherapy (cladribine and low-dose cytarabine) could help people with treated secondary acute myeloid leukemia (AML). Secondary AML is a type of leukemia that develops after treatment for another bon…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New liposome combo shows promise for Tough-to-Treat leukemia
Disease control CompletedThis study tested a new formulation of two chemotherapy drugs (CPX-351) in 56 adults with newly diagnosed acute myeloid leukemia (AML) who were at high risk of not responding to standard treatment. The goal was to find the best dose and see how well it worked to stop cancer cells…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can antibody infusions shield CLL patients from deadly infections?
Disease control CompletedThis study tested whether regular infusions of Panzyga (a concentrated antibody solution from donated blood) could prevent serious infections in people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. The trial included 247 adults with CLL who were recei…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Immune cell infusion shows promise against post-transplant blood cancer relapse
Disease control CompletedThis early-phase study tested whether specially grown immune cells (cytokine-induced killer cells) could safely treat blood cancers that return after a stem cell transplant. 21 adults with relapsed multiple myeloma or other blood cancers received these donor cells. The goal was t…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for rare blood disorder: ravulizumab trial shows promise in china
Disease control CompletedThis completed Phase 3 trial tested ravulizumab in 18 adults in China with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The study measured changes in LDH, a marker of red blood cell breakdown, to see if the drug could control the…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New lymphoma treatment aims to boost cure rates and cut radiation risks
Disease control CompletedThis study tested a combination of brentuximab vedotin and AVD chemotherapy in 118 adults with newly diagnosed, early-stage Hodgkin lymphoma that is considered unfavorable. The goal was to see if this treatment could cure more patients while reducing long-term side effects, espec…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Tailored treatments for kids with rare hodgkin lymphoma show promise
Disease control CompletedThis phase II trial studied how well surgery, chemotherapy, and radiation work in 188 children with newly diagnosed, low-stage lymphocyte predominant Hodgkin disease. The goal was to find effective treatments that minimize side effects. Patients received different therapies based…
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New chemo cocktail shows promise in myeloma stem cell transplants
Disease control CompletedThis phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug cocktail shows promise against tough leukemia
Disease control CompletedThis study tested a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 adults with a rare, aggressive leukemia called Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia in blast phase. The goal was to see if the drugs cou…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for PNH patients: Long-Term drug safety confirmed
Disease control CompletedThis study tested the long-term safety of a drug called pegcetacoplan in people with PNH, a rare blood disease that destroys red blood cells. All 137 participants had already completed a prior pegcetacoplan study and continued treatment. The main goal was to track side effects ov…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for Hard-to-Treat myeloma: teclistamab trial in japan
Disease control CompletedThis study tested teclistamab, a drug that helps the immune system find and attack myeloma cells, in 40 Japanese patients whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and find the right dose in phase 1, then see how well it …
Phase: PHASE1, PHASE2 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough leukemia: targeted drug combo shows promise in large trial
Disease control CompletedThis large phase III trial tested whether adding the targeted drug dasatinib to standard chemotherapy improves outcomes for children and young adults with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (B-ALL), including those with certain genetic mutations. Nearly…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Iron pills for babies: daily or weekly? new study has answers
Disease control CompletedThis study tested whether giving iron supplements daily or weekly works better to prevent anemia in healthy Thai infants aged 6 to 12 months. A total of 287 babies were randomly assigned to receive iron daily or weekly for 3 months, then all switched to weekly for another 3 month…
Phase: NA • Sponsor: Mahidol University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy shows promise for tough lymphoma cases
Disease control CompletedThis phase 2 trial tested a combination of two treatments—CD19/22 CAR-T cells (a type of immune cell therapy) and tislelizumab (a PD-1 inhibitor that helps immune cells attack cancer)—in 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal was to see if t…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage study tested two experimental drugs, odronextamab and cemiplimab, in 105 patients with aggressive B-cell lymphoma that had stopped responding to other treatments. The main goal was to check safety and find the best dose. Researchers also looked at how well the dr…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a Gene-Targeting drug boost chemo for older leukemia patients?
Disease control CompletedThis study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill for rare blood cancers shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
One cord blood unit may replace two in stem cell transplants for blood cancer
Disease control CompletedThis study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how l…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill shows promise for rare blood disorder aHUS
Disease control CompletedThis study tested a new oral medication called iptacopan in 34 adults with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots, low platelets, and kidney damage. The goal was to see if the drug could improve blood counts and kidney function w…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug may tame Life-Threatening side effects of cancer immunotherapy
Disease control CompletedThis study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New gel blocks blood flow to tumors and stops bleeding
Disease control CompletedThis study looked at how well a gel-like material called Obsidio works to block blood vessels in people with hypervascular tumors or bleeding. 125 adults were treated, and researchers checked if the vessels were successfully blocked and if there were any serious side effects with…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for kids with bleeding disorder: drug boosts platelets in phase 3 trial
Disease control CompletedThis study tested a medication called avatrombopag in 75 children aged 1 to 17 with immune thrombocytopenia (ITP) lasting at least 6 months. ITP is a condition where the immune system destroys platelets, raising the risk of bruising and bleeding. The goal was to see if the drug c…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Supercharged immune cells take on tough lymphoma
Disease control CompletedThis completed Phase 2 trial tested a special type of immune cell therapy called CAR-T in 168 patients with relapsed or refractory non-Hodgkin lymphoma. The CAR-T cells were designed to recognize four different targets on cancer cells (CD19, CD20, CD22, and CD30). Patients receiv…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill shows promise in shrinking spleens for myelofibrosis patients
Disease control CompletedThis study tested a new drug called TQ05105 in 107 people with moderate to high-risk myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen. The goal was to see if TQ05105 could shrink the spleen better than the standard drug hydroxyurea. Participants too…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for low platelets: avatrombopag tested in japanese ITP patients
Disease control CompletedThis study tested a drug called avatrombopag in 19 Japanese adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal was to see if the drug could safely increase platelet counts over 26 weeks. Parti…
Phase: PHASE3 • Sponsor: Sobi, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to improve survival in aggressive leukemia
Disease control CompletedThis large phase III trial tested whether adding the drugs bortezomib and sorafenib to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) live longer without the cancer returning. Over 1,600 participants took part. The study focused on patients w…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for PNH patients in china: eculizumab shows promise
Disease control CompletedThis study tested eculizumab in 25 adults with PNH in China who had not previously taken complement inhibitors. Participants received infusions over 62 weeks. The main goal was to see if the drug reduced LDH levels, a marker of disease activity. Results showed a decrease in LDH, …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Intense Pre-Transplant combo shows promise for tough leukemias
Disease control CompletedThis phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo tackles tough lymphoma
Disease control CompletedThis study tested a new combination treatment for people with a type of blood cancer (B-cell non-Hodgkin's lymphoma) that did not respond to standard therapies. The treatment combined a drug (XPO-1 inhibitor) with specially engineered immune cells (CAR-T cells). The goal was to s…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail shows promise for myeloma patients ineligible for transplant
Disease control CompletedThis phase 3 study tested whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, dexamethasone) helps people with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. The main goal was to see if more patients achieve a …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Real-World study confirms Mogamulizumab's effectiveness against rare skin cancer
Disease control CompletedThis study looked at 100 adults with cutaneous T-cell lymphoma (a rare type of skin cancer) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measur…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo shows promise for High-Risk leukemia patients
Disease control CompletedThis study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemothera…
Phase: PHASE3 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Protein and exercise combo tested to fight muscle loss in sick kids
Disease control CompletedThis pilot study tested whether giving critically ill children on breathing machines extra protein along with a personalized exercise program could help preserve muscle mass and improve recovery. The trial enrolled 18 children in the ICU and measured how feasible and safe the app…
Phase: NA • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental drug targets tough blood cancers in first human trial
Disease control CompletedThis early-stage trial tested an experimental drug called SAR442257 in 47 adults with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might fight t…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a biomarker predict who responds to a new AML combo?
Disease control CompletedThis phase 2 trial tested whether certain biomarkers in bone marrow can predict how well patients with high-risk acute myeloid leukemia (AML) respond to treatment with sirolimus plus standard chemotherapy (MEC). The study enrolled 39 adults with AML that was hard to treat or had …
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough lymphoma: targeted drug shows promise
Disease control CompletedThis phase 2 trial tested a drug called zilovertamab vedotin (MK-2140) in 140 people with diffuse large B-cell lymphoma that had returned or stopped responding to at least two prior treatments. The goal was to see how many patients had their tumors shrink or disappear. The study …
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Massive trial seeks best chemo cocktail for kids with leukemia
Disease control CompletedThis large phase 3 trial enrolled over 9,000 children with newly diagnosed standard-risk B-ALL or localized B-LLy. Researchers tested different combinations and doses of chemotherapy drugs to see which worked best with the fewest side effects. The goal was to improve disease-free…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New pill aims to keep leukemia at bay after transplant
Disease control CompletedThis early-phase trial tested a drug called ONC-201 in 20 people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who had recently received a stem cell transplant. Participants took the drug by mouth once a week for a year to see if it was safe and co…
Phase: PHASE1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a common pain reliever boost a cancer drug? early trial underway
Disease control CompletedThis early-phase trial tested a combination of two drugs—selinexor and choline salicylate (a type of aspirin)—in 22 adults with certain lymphomas or multiple myeloma that had come back or not responded to treatment. The main goal was to find the safest dose and check for side eff…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo may make cord blood transplants safer for blood cancer patients
Disease control CompletedThis study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Gut bacteria drug shows promise against blood disorder
Disease control CompletedThis early-phase study tested whether the oral antibiotic rifaximin can reduce abnormal proteins in people with monoclonal gammopathy, a condition that can lead to blood cancers. Fifty adults with different types of gammopathy took the drug to see if it lowered their immunoglobul…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New chemo cocktail aims to beat back leukemia relapse
Disease control CompletedThis phase 2 trial tests whether a combination of clofarabine and intermediate-dose cytarabine (CLARA) works better than high-dose cytarabine (HDAC) alone as consolidation therapy for younger adults (18-60) with newly diagnosed acute myeloid leukemia (AML). After initial remissio…
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug may offer longer-lasting bleed control for rare platelet disorder
Disease control CompletedThis lab study tested whether concizumab, a drug that blocks a natural clotting inhibitor, can improve blood clotting in people with Glanzmann thrombasthenia (GT), a rare genetic bleeding disorder. Blood samples from 20 adults with GT and healthy donors were mixed with concizumab…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a second-line drug help CML patients stay cancer-free without daily pills?
Disease control CompletedThis study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy for hemophilia b shows promise in Long-Term study
Disease control CompletedThis study follows 9 adults with severe or moderately severe hemophilia B who received a one-time gene therapy (AAV5-hFIX) to help their bodies produce clotting factor IX. Researchers are checking if the treatment remains safe and effective for up to 10 years after the initial do…
Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy shows promise for lymphoma in seniors
Disease control CompletedThis study tested a treatment plan for adults aged 65 to 80 with a type of lymphoma (large B-cell). The plan combined standard chemotherapy with targeted antibodies and a radioactive drug. The goal was to see if this approach could better control the cancer. The study involved 30…
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug may help liver transplant patients avoid bleeding complications
Disease control CompletedThis study looked at whether the drug avatrombopag can safely and effectively raise platelet counts in people who develop dangerously low platelets after a liver transplant. Researchers compared 67 patients who received the drug with 67 similar patients who got standard care. The…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo therapy shows promise for older hodgkin lymphoma patients
Disease control CompletedThis phase II trial tested a combination of the targeted drug brentuximab vedotin with standard chemotherapy (AVD) in 49 older adults with untreated Hodgkin lymphoma. The goal was to see how many patients achieved complete remission. The approach aims to improve outcomes by targe…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental 'In-Situ' vaccine aims to train immune system against three cancers
Disease control CompletedThis early-phase trial tested a combination of four therapies to see if they could safely boost the immune system to fight cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head & neck cancer received low-dose radiation and two immune-boosting drugs inje…
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Real-World data shows Tirabrutinib's promise for rare brain cancer
Disease control CompletedThis study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see…
Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for tough MDS: drug trio targets resistant cancer cells
Disease control CompletedThis study tested a three-drug combination (navitoclax, venetoclax, and decitabine) in 6 adults with high-risk myelodysplastic syndrome (MDS) that came back or didn't respond to standard therapy. The goal was to find the safest dose and see if the combo could shrink or control th…
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Zapping tumors with precision radiation may help control limited metastatic breast cancer
Disease control CompletedThis study looked at whether adding focused radiation (SBRT) or surgery to standard treatments like chemo or hormone therapy helps people with breast cancer that has spread to just one or two places. 129 participants were randomly assigned to get standard care alone or standard c…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Iron fix: new study tests best way to boost energy in women with hidden deficiency
Disease control CompletedThis study looked at 1331 women aged 18-45 who had low iron stores but normal hemoglobin (no anemia). They were split into three groups: one got daily oral iron pills for 3 months, another got three IV iron infusions over 3 months, and a third got no treatment. The goal was to se…
Phase: NA • Sponsor: Akram Medical Complex • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for kids with tough leukemia: experimental combo tested
Disease control CompletedThis early-phase study tested a combination of three chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or didn't respond to standard treatment. The main goals were to find the best dose and check for side effects. …
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Leukemia drug holiday: study finds many can stop imatinib without relapse
Disease control CompletedThis study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental combo targets Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Real-world data: luspatercept may cut transfusion needs in MDS patients
Disease control CompletedThis study looked at 88 adults in China with lower-risk myelodysplastic syndromes (MDS) who had not received prior treatment with erythropoiesis-stimulating agents. They were given luspatercept, and researchers tracked how many became free from red blood cell transfusions and whe…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New blood thinner may simplify stroke prevention after heart surgery
Disease control CompletedThis study tested whether a newer blood thinner, rivaroxaban (Xarelto), is as safe and effective as the older drug warfarin for preventing strokes in people who develop atrial fibrillation after heart surgery. About 100 adults who had open-heart surgery and then experienced a new…
Phase: PHASE3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
CAR T-Cell therapy shows promise for Hard-to-Treat multiple myeloma
Disease control CompletedThis study tested a treatment called anti-BCMA CAR T-cell therapy in 40 adults with multiple myeloma whose disease did not respond well enough to a stem cell transplant and maintenance therapy. The goal was to see if this one-time cell therapy could help more patients achieve a c…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Immunotherapy after transplant shows promise for tough lymphomas
Disease control CompletedThis study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with relapsed or hard-to-treat Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma. The goal was to …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for AML patients: drug combo targets leukemia cells
Disease control CompletedThis study tested a new drug called S65487, which blocks a protein that helps leukemia cells survive, combined with the standard drug azacitidine. The trial included 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive chemotherapy. Researcher…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Next-Day clinic aims to cut hospital admissions for common ailments
Disease control CompletedThis study tested a new clinic that sees emergency room patients the next day for conditions like pneumonia, heart failure, and kidney injury. The goal was to avoid hospital stays and improve patient care. About 570 adults took part, and researchers measured how many days they we…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Early trial checks safety of blinatumomab in japanese leukemia patients
Disease control CompletedThis early-phase study tested the safety of the drug blinatumomab (Blincyto®) in 6 Japanese adults newly diagnosed with a type of leukemia called B-ALL. The main goal was to see what side effects occurred. Researchers also looked at how the drug moves through the body and whether…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New antibody shows promise in slowing early myeloma
Disease control CompletedThis phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Calquence capsules pass Real-World safety check in CLL patients
Disease control CompletedThis completed study looked at the safety of Calquence (acalabrutinib) capsules in 67 people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Researchers tracked side effects like infections and bone marrow problems during everyday use. …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Promising combo tackles FLT3 leukemia in early trial
Disease control CompletedThis early-phase study tested whether adding two targeted drugs, gemtuzumab ozogamicin and midostaurin, to standard chemotherapy is safe for people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that has a FLT3 mutation. The trial enrolled 21 adults and a…
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Old drug, new hope for rare skin cancer?
Disease control CompletedThis study tested the drug lenalidomide (Revlimid) in 19 people with a rare type of skin lymphoma called leg-type large B-cell lymphoma that had come back or not responded to initial chemotherapy. Participants took lenalidomide pills daily for 21 days, then rested for 7 days, rep…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Early trial explores new drug for blood cancers in japanese patients
Disease control CompletedThis early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug l…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for kids with rare bleeding disease: study tests rVWF therapy
Disease control CompletedThis study tested a medicine called vonicog alfa (rVWF), sometimes given with another drug (ADVATE), to control bleeding in 47 children under 18 with severe von Willebrand disease. The treatment was given for 12-18 months, and doctors checked how well it stopped bleeding and if i…
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for rare gut disease? small study tests biologic drug
Disease control CompletedThis study tested a drug called ustekinumab in 8 people with a rare, severe form of Behçet's syndrome affecting the gut, along with a blood disorder called myelodysplastic syndrome. The goal was to see if the drug could control gut symptoms and reduce disease activity over 24 wee…
Phase: PHASE2 • Sponsor: Liu Tian • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for untreated lymphoma patients
Disease control CompletedThis study tested a combination of three targeted drugs (mosunetuzumab, polatuzumab vedotin, and obinutuzumab) in 42 people with untreated slow-growing B-cell non-Hodgkin lymphoma. The goal was to see how many patients achieved a complete response (no cancer detected). The drugs …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immunotherapy combo shows promise for Post-Transplant leukemia relapse
Disease control CompletedThis phase 1 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 29 patients whose acute myeloid leukemia or myelodysplastic syndrome came back or did not respond after a donor stem cell transplant. The goal was to find the safest dose and see if the drugs could he…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Last hope? new combo targets myeloma that resists standard drugs
Disease control CompletedThis phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Gene-Editing breakthrough offers hope for blood disorder patients
Disease control CompletedThis early-stage study tested a new gene-edited stem cell transplant in 2 children with severe β-thalassemia, a serious blood disorder requiring lifelong transfusions. The treatment aims to help the body produce healthy red blood cells and reduce or stop the need for transfusions…
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Second stem cell transplant shows promise for returning myeloma
Disease control CompletedThis study tested a combination of two drugs, busulfan and bortezomib, given before a second stem cell transplant in 30 patients with multiple myeloma that had returned after a previous transplant. The goal was to see if this approach could control the disease. Results showed tha…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for older AML patients: triple drug combo aims to control disease and prevent relapse
Disease control CompletedThis study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who were not eligible for standard chemotherapy. The goal was to quickly control …
Phase: PHASE1, PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New transplant strategy shows promise for blood cancer relapse
Disease control CompletedThis study tested a stem cell transplant approach for adults with relapsed follicular lymphoma, a type of blood cancer. The treatment included the drug rituximab to help control the disease and prevent complications. The goal was to see if this strategy could improve survival and…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Turmeric and black pepper extract shows promise in slowing early cancers
Disease control CompletedThis study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug safety check for tough blood cancer
Disease control CompletedThis study looked at how safe and tolerable the drug Kyprolis is for Indian patients whose multiple myeloma has come back or stopped responding to treatment. A total of 101 adults took part, and researchers tracked side effects and how long the drug kept the cancer from getting w…
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can a simple drink help blood cancer patients recover from stem cell transplants?
Disease control CompletedThis study tested whether a special oral nutritional supplement (Ensure Complete) could help patients with blood cancer maintain weight and gut health after a stem cell transplant. One hundred participants were randomly assigned to receive either the supplement or a standard hosp…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental drug combo targets tough blood cancers
Disease control CompletedThis early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Rabbit antibodies show promise for rare bone marrow disease
Disease control CompletedThis phase 2 trial tested a combination of rabbit antithymocyte globulin (Thymoglobuline) and ciclosporin in 35 people with acquired aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal was to see if this rabbit-based immune-suppressing tre…
Phase: PHASE2 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug shows promise in early trial for rare blood disorder
Disease control CompletedThis early study tested an experimental drug called OMS906 (zaltenibart) in 15 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where red blood cells break apart. The main goal was to check safety and how the body handles the drug. Researchers also look…
Phase: PHASE1 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New malaria combo shows promise in kids – could fight drug resistance
Disease control CompletedThis study tested a new two-drug combination (KAF156 plus a special form of lumefantrine) in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment safely clears the parasite and prevents the infection from coming back. The approac…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New triple-drug combo shows promise for hard-to-treat leukemia patients
Disease control CompletedThis early-phase study tested a new drug called siremadlin added to two existing drugs (venetoclax and azacitidine) for adults with acute myeloid leukemia (AML) who are too frail for standard chemotherapy. The study included 14 people whose cancer did not respond well to initial …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New malaria combo shows promise in clearing parasite
Disease control CompletedThis study tested a combination of two anti-malarial drugs, cipargamin and KLU156, in 60 people with uncomplicated Plasmodium falciparum malaria. Participants were at least 12 years old and had a confirmed infection. The main goal was to see if the drugs could clear the malaria p…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New pill could reduce Blood-Letting for rare blood cancer patients
Disease control CompletedThis phase 2 study tested an oral drug called bomedemstat in 20 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The main goal was to see if the drug could safely lower red blood cell levels enough to avoid routine blood removal (phlebotomy…
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of two drugs, nivolumab and cabiralizumab, in 4 adults with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or not responded to prior treatments. The goal was to see if the drug pair could shrink tumors. The …
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Real-World check: newer PNH drug holds up in routine care
Disease control CompletedThis study followed 120 adults with paroxysmal nocturnal hemoglobinuria (PNH) who switched from the older drug eculizumab to the newer ravulizumab. Researchers measured changes in a blood marker called LDH to see if the new drug controlled red blood cell breakdown just as well or…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy shows promise for myeloma relapse after transplant
Disease control CompletedThis study tested a two-step treatment for people whose multiple myeloma returned after a donor stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce cancer and prepare the immune system. Then, they received donor immune cells (lymphocyte infusio…
Phase: PHASE2 • Sponsor: Ciusss de L'Est de l'Île de Montréal • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New lymphoma combo shows promise in major trial
Disease control CompletedThis large Phase 3 trial tested whether adding polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the usual treatment (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants received either the new combo or the standard regime…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a common arthritis drug tame rare immune disease Flare-Ups?
Disease control CompletedThis study tested the drug tofacitinib (Xeljanz) in 10 adults with chronic granulomatous disease (CGD) who had ongoing inflammation in the gut, skin, or lungs. Participants took the pill daily for 3 months to see if it was safe and could help control symptoms. The goal was to fin…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New pill shows promise for rare blood disorder
Disease control CompletedThis study tested an experimental pill called Bomedemstat in 73 people with essential thrombocythemia, a rare blood condition causing too many platelets. Participants had already tried at least one standard treatment without success. The main goals were to check safety and see if…
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a drug shorten dialysis for kids with a rare kidney disease?
Disease control CompletedThis study tested whether the drug eculizumab (Soliris) can help children with a severe kidney condition called STEC-HUS recover faster. The trial gave 100 children either eculizumab or a placebo over several weeks. The main goal was to see if the drug reduces the number of days …
Phase: PHASE3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Pill may replace shots for blood cancer patients, study finds
Disease control CompletedThis study tested whether an oral medication (CC-486) could help elderly patients with a serious blood disorder called myelodysplastic syndrome (MDS) maintain their improvement after initial injectable treatment. Eleven patients who had responded to injectable azacitidine switche…
Phase: PHASE2 • Sponsor: University of Florence • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug may help MDS patients need fewer blood transfusions
Disease control CompletedThis study tested a drug called luspatercept in 30 adults from China and Japan who have a bone marrow disorder (MDS) and need regular red blood cell transfusions. The goal was to see if the drug could help them go without transfusions for at least 8 weeks. The drug works by helpi…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill aims to cut sickle cell pain crises
Disease control CompletedThis completed Phase 2 trial tested an oral drug called epeleuton in 35 adults with sickle cell disease. The goal was to see if it could reduce painful vaso-occlusive crises and improve blood cell health. Participants took 2000 mg capsules twice daily for 16 weeks, and researcher…
Phase: PHASE2 • Sponsor: Afimmune • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New dosing strategy aims to tame eye side effects in myeloma drug
Disease control CompletedThis study tested different dosing schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to see if changing the dose or how often it is given could reduce serious eye…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could two old drugs free thalassemia patients from lifelong transfusions?
Disease control CompletedThis phase 2 trial tested whether combining thalidomide and hydroxyurea can reduce the need for blood transfusions in people with transfusion-dependent beta thalassemia. The study enrolled 100 patients over age 2 in Pakistan, where thalassemia is common and life expectancy is low…
Phase: PHASE2 • Sponsor: Pakistan Blood and Marrow Transplant (PBMT) Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough blood cancers? early trial tests LYT-200
Disease control CompletedThis early-stage study tested a new drug called LYT-200 in 101 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had come back or stopped responding to treatment. The main goals were to check the drug's safety and find the right dose. While not…
Phase: PHASE1 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New radiation technique aims to safely prepare blood cancer patients for transplant
Disease control CompletedThis study tested a new way to deliver total body radiation to adults with blood cancers who need a stem cell transplant. The goal was to see if this method could effectively target cancer while protecting the lungs. 36 patients took part, and the study focused on safety and how …
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a gout drug protect kidneys in cancer patients?
Disease control CompletedThis study tested pegloticase, a drug used for gout, in 10 cancer patients with high uric acid from tumor lysis syndrome. The goal was to see if it could quickly lower uric acid levels and protect kidney function. It was a small pilot trial to gather early data.
Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug ABC008 tested for rare blood cancer
Disease control CompletedThis study tested a new drug called ABC008 in 21 adults with T-cell large granular lymphocytic leukemia (T-LGLL), a rare blood cancer. The drug was given as a shot under the skin. The main goal was to check for side effects and see how the drug affects blood counts and other lab …
Phase: PHASE1, PHASE2 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antibody infusion shows promise for immune deficiency patients
Disease control CompletedThis study tested a new intravenous immunoglobulin (IVIg) treatment called Kedrion IVIg 10% in 47 people with primary immunodeficiency, a condition where the immune system cannot make enough antibodies. The goal was to see if regular infusions of this antibody therapy could preve…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
High-Dose chemo and stem cell transplant shows promise for HIV lymphoma patients
Disease control CompletedThis early-phase trial tested whether high-dose chemotherapy followed by a stem cell transplant is safe and feasible for 25 people with HIV who also have lymphoma. The goal was to see how well the body recovers and to monitor side effects. Results could point to a new treatment p…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for Tough-to-Treat myeloma: experimental drug shows promise
Disease control CompletedThis study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThis phase 2 trial tested a drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or not responded to prior treatments. Participants received the drug intravenously every two weeks. The main goal was to see how many patients' tumors shrank or disappe…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immune combo shows promise against stubborn lymphoma
Disease control CompletedThis study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shr…
Phase: PHASE2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental combo targets stubborn leukemia in tiny trial
Disease control CompletedThis early-phase trial tested a combination of two drugs, enasidenib and cobimetinib, in just 3 patients with a specific form of acute myeloid leukemia (AML) that had come back or didn't respond to treatment. The goal was to see if the combination was safe and to find the best do…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill could help adults with low platelet disorder
Disease control CompletedThis Phase 3 trial tested an oral drug called HMPL-523 (sovleplenib) in 272 adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants who had not responded well to prior treatments received eith…
Phase: PHASE3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug shows promise in wiping out hidden myeloma cells after transplant
Disease control CompletedThis study tested a drug called daratumumab in 49 people with multiple myeloma who were eligible for a stem cell transplant. The goal was to see if daratumumab could help eliminate any remaining cancer cells in the bone marrow after the transplant. While the treatment aims to con…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for kids with rare blood disorder: drug may cut flares and steroid use
Disease control CompletedThis study tested the drug mepolizumab in 16 children aged 6 to 17 with hypereosinophilic syndrome (HES), a rare condition causing too many eosinophils (a type of white blood cell). The goal was to see if mepolizumab could reduce disease flares and lower the need for steroids ove…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill shows promise against tough blood cancers
Disease control CompletedThis early-stage trial tested an oral drug called NTX-301 in 22 adults with certain blood cancers (MDS, AML, or CMML) that had not responded to prior treatments. The main goal was to check safety and find the right dose. Researchers also looked for signs that the drug might help …
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New study checks bleeding risk when CLL drug meets blood thinners
Disease control CompletedThis study observed 45 people with chronic lymphocytic leukemia (CLL) who were taking the drug acalabrutinib (Calquence) along with a direct oral anticoagulant (DOAC), a type of blood thinner. The main goal was to see how many patients had serious bleeding events while on this co…
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Promising new drug shows hope for rare anemia patients
Disease control CompletedThis study tested a drug called mitapivat (AG-348) in 52 adults with pyruvate kinase deficiency, a rare genetic condition that causes red blood cells to break down too quickly, leading to anemia. The goal was to see if different doses of the drug are safe and help control the dis…
Phase: PHASE2 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Tiny trial hopes drug can ease liver damage in rare triple condition
Disease control CompletedThis completed phase 2 trial tested a drug called foscenvivint in just 5 people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. The goal was to see if the drug could improve liver function scores over 24 weeks. Because the study is very s…
Phase: PHASE2 • Sponsor: Kiminori Kimura, MD • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Stem cell transplant study seeks best way to prevent immune attack
Disease control CompletedThis study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for young leukemia patients: combination chemo shows promise
Disease control CompletedThis study tested a combination of chemotherapy drugs in 318 adolescents and young adults (ages not specified but typically 15-39) with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see how well the treatment worked at killing cancer cells and stopping the d…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for sickle cell: Half-Matched transplants show promise
Disease control CompletedThis phase 2 trial tested a half-matched (haploidentical) bone marrow transplant in 95 children and adults with severe sickle cell disease. The goal was to see if this approach could help patients live without major complications for two years. Participants received a reduced-int…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo shows promise for rare blood cancer
Disease control CompletedThis completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …
Phase: PHASE2 • Sponsor: Won Seog Kim • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New stem cell transplant approach shows promise for blood disorders
Disease control CompletedThis pilot study tested a stem cell transplant from closely matched unrelated donors for 8 patients with severe sickle cell disease or thalassemia major. The donated stem cells were specially processed to remove certain immune cells to reduce the risk of rejection and graft-versu…
Phase: NA • Sponsor: Timothy Olson • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells show promise against tough childhood cancers
Disease control CompletedThis phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody shows promise for rare blood cancers
Disease control CompletedThis phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug is an antibody that targets a protein on cancer cells. It was given alone or with chemotherapy to see if it could shr…
Phase: PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo shows promise for aggressive myeloma
Disease control CompletedThis study tested adding elotuzumab to a standard three-drug combination (bortezomib, lenalidomide, dexamethasone) for people newly diagnosed with high-risk multiple myeloma, a blood cancer that tends to come back quickly. The goal was to find the safest dose of elotuzumab and se…
Phase: PHASE1, PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can a daily powder boost iron levels in women? new study investigates
Disease control CompletedThis study tested whether a mineral-enriched powder taken daily for six months could raise blood iron levels in women aged 18-35 with iron deficiency. Participants mixed the powder or a placebo into water and provided blood samples monthly. The goal was to see if the powder reduc…
Phase: PHASE2 • Sponsor: Carleton University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can metformin or hydroxyurea cut transfusions for thalassemia patients?
Disease control CompletedThis completed Phase 4 trial tested two drugs—hydroxyurea and metformin—in 96 people with transfusion-dependent beta-thalassemia. Participants took one of the two drugs for a year. Researchers measured changes in fetal hemoglobin levels and how often blood transfusions were neede…
Phase: PHASE4 • Sponsor: Bahria University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo offers hope for aggressive lymphoma in diverse patients
Disease control CompletedThis study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New weekly shot shows promise for rare bleeding disorder
Disease control CompletedThis study tested a new medicine called HBM9161, given as a weekly shot under the skin, for adults with primary immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising the risk of bleeding. The trial included 36 people who had not responded…
Phase: PHASE2, PHASE3 • Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New targeted pill shows promise for rare blood cancer
Disease control CompletedThis Phase 2 study tested avapritinib, a daily tablet that targets a specific genetic mutation, in 107 people with advanced systemic mastocytosis (a rare blood cancer). The main goal was to see how many patients had their tumors shrink or symptoms improve. Results suggest the dru…
Phase: PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could an antibiotic beat eye cancer? new trial tests doxycycline for lymphoma
Disease control CompletedThis phase 2 trial tested the antibiotic doxycycline as a first treatment for a rare type of eye lymphoma (OAMZL) that may be linked to a bacterial infection. 44 newly diagnosed patients took doxycycline for several months. The goal was to see if eradicating the infection could c…
Phase: PHASE2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Japanese hemophilia b patients monitored on refixia – no surprises found
Disease control CompletedThis study followed 28 people with hemophilia B in Japan who were already prescribed Refixia as part of their normal care. Researchers tracked side effects, bleeding episodes, and quality of life to confirm the drug's safety and effectiveness over time. The study did not test a n…
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to tame hairy cell leukemia with fewer side effects
Disease control CompletedThis study tested a combination of two drugs—vemurafenib (taken by mouth) and rituximab (given by IV)—in 15 people with hairy cell leukemia, a rare blood cancer. The goal was to see if this treatment works as well as or better than standard chemotherapy, but with fewer side effec…
Phase: PHASE2 • Sponsor: Scripps Health • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for rare bone marrow failure
Disease control CompletedThis study tested whether adding eltrombopag to standard immunosuppressive therapy improves early recovery in patients with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. 202 participants received either standard treatment (horse a…
Phase: PHASE3 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
AI reads MRI scans to spot brain tumors without surgery
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-Astro23 can identify a specific type of brain tumor (IDH mutant astrocytoma) from routine MRI scans. Researchers are using existing MRI data from 1,372 patients to train and evaluate the AI. If accurate, t…
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New scan could spot lymphoma without PET
Diagnosis CompletedThis early study tested a new radioactive tracer called 99mTc-1-thio-D-glucose in 16 adults with Hodgkin or non-Hodgkin lymphoma. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it went in the body. The goal was to check safety and whether the …
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
Spit test could spot gum disease early
Diagnosis CompletedThis study looked at whether certain proteins in saliva can help tell the difference between healthy gums, gingivitis (mild gum inflammation), and periodontitis (serious gum disease). Researchers collected saliva from 60 people and measured three specific biomarkers. The goal is …
Phase: NA • Sponsor: Izmir Katip Celebi University • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New fingerstick test for blood thinner monitoring put to the test
Diagnosis CompletedThis study tested how well a small, portable device (LumiraDx) measures blood clotting (INR) compared to standard lab tests. Researchers collected blood from 420 adults, some taking warfarin and some not, using both a fingerstick and a vein draw. The goal was to see if the device…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Fingerprick test for blood thinners put to the test
Diagnosis CompletedThis study tested whether a fingerstick blood test (LumiraDx INR test) gives accurate results for people taking the blood thinner phenprocoumon. Researchers compared fingerstick results to standard lab tests in 102 adults. The goal is to see if this quick test can reliably monito…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New imaging method could speed up diagnosis of blood clotting disorders
Diagnosis CompletedThis study tested a new diagnostic tool that uses imaging flow cytometry to examine platelets in blood samples. Researchers compared it to standard lab tests in 31 patients suspected of having platelet disorders or heparin-induced thrombocytopenia. The goal was to see if the new …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New blood test could speed up Life-Saving treatment for HUS patients
Diagnosis CompletedThis study tested a new blood test designed to quickly determine whether the complement system is involved in a serious kidney condition called thrombotic microangiopathy (TMA). The test measures complement deposits on cells in a lab sample. Researchers compared test results to h…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New PET tracer aims to spot hidden cancers without biopsy
Diagnosis CompletedThis completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
New ultrasound could spot heart trouble before It's too late for chemo patients
Diagnosis CompletedThis study tested whether a special heart ultrasound (2D strain imaging) can detect early signs of heart damage caused by anthracycline chemotherapy in 100 leukemia patients. The goal is to catch problems sooner, so doctors can adjust treatment and reduce the risk of permanent he…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:39 UTC
-
Protein fingerprints may spot hidden transplant rejection
Diagnosis CompletedThis study tested whether analyzing proteins from kidney biopsy and urine samples can improve the diagnosis of microvascular inflammation, a key sign of antibody-mediated rejection in kidney transplant recipients. Researchers used mass spectrometry to find protein signatures in 1…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:38 UTC
-
New PET tracer shows promise for spotting myeloma bone lesions
Diagnosis CompletedThis study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Blood test may spot deadly transplant complication earlier
Diagnosis CompletedThis completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New shot may shield transplant patients from deadly immune attack
Prevention CompletedThis study tested a drug called abatacept, given as a shot under the skin, to prevent a serious complication called graft-versus-host disease (GVHD) in 29 adults with blood cancers. Participants received a stem cell transplant from a half-matched donor. The goal was to see if aba…
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New antibody shot shows promise in preventing malaria in african women
Prevention CompletedThis study tested whether a single dose of an antibody called L9LS can safely prevent malaria in women of childbearing age in Mali. 279 healthy women and men received either the antibody or a placebo and were monitored for 24 weeks. The goal was to see if the antibody could block…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 27, 2026 13:05 UTC
-
New antibiotic may replace standard infection prevention in blood cancer patients
Prevention CompletedThis study tested whether fosfomycin, an older antibiotic, works as well as ciprofloxacin for preventing serious infections in people with blood cancers like leukemia or those receiving a stem cell transplant. 177 adults from 11 Spanish hospitals took part. The main goal was to s…
Phase: PHASE3 • Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias • Aim: Prevention
Last updated Jun 27, 2026 13:01 UTC
-
New shot could shield against malaria for months
Prevention CompletedThis study tested a new drug called MAM01 to see if it is safe and could help prevent malaria for at least 4 months. It involved 125 healthy adults and children living in parts of Africa where malaria is common. Researchers gave different doses of MAM01 or a placebo and monitored…
Phase: PHASE1 • Sponsor: Gates Medical Research Institute • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Text reminders help get young kids vaccinated on time
Prevention CompletedThis study tested whether sending text message reminders to parents could increase routine vaccination rates in children aged 0-2 years. Over 1,000 families in Brooklyn, New York, whose children were behind on vaccines received texts when shots were due or coming due. The goal wa…
Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
New 'Star Homes' aim to slash childhood disease in tanzania
Prevention CompletedThis study tested whether specially built houses (Star Homes) could reduce malaria, respiratory infections, and diarrhea in children under 13 in rural Tanzania. Over 1,100 children lived either in a Star Home or a traditional mud house. The Star Homes have screened windows, solar…
Phase: NA • Sponsor: University of Oxford • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New drug aims to block sickle cell pain crises
Prevention CompletedThis study tested a drug called crovalimab in 95 people with sickle cell disease to see if it could prevent vaso-occlusive episodes (painful blockages in blood vessels). Participants received either crovalimab or a placebo alongside their usual treatments. The goal was to measure…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Prevention
Last updated Jun 27, 2026 12:26 UTC
-
Could targeted drug dosing stamp out malaria in thai hotspots?
Prevention CompletedThis study tested whether giving antimalarial drugs to everyone in high-risk villages and forest workers could lower malaria cases in Thailand. Over 14,000 people took part. The goal was to see if this approach reduces infections from both Plasmodium falciparum and Plasmodium viv…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
New prosthetic grows with kids: no more frequent replacements?
Symptom relief CompletedThis study is testing a new type of prosthetic leg for children aged 3 to 18 that can be easily adjusted as they grow. The device is designed to be fitted in a single session and adjusted by the wearer. Researchers will measure comfort, socket pressure, walking speed, and quality…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Can exercise help older adults with sickle cell disease?
Symptom relief CompletedThis study tested a personalized exercise program called Gerofit for older adults with sickle cell disease. The goal was to see if the program is safe, doable, and helps improve physical health and quality of life. Thirty participants took part in tele-exercise sessions focusing …
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Which exercise helps kids bounce back after leukemia? new study tests two approaches
Symptom relief CompletedThis study looked at 72 children aged 10-18 who finished chemotherapy for acute lymphoblastic leukemia. Researchers compared two types of aerobic exercise—one with a steady intensity and one that gradually increases—to see which better improves heart and lung fitness. All kids ex…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Cartoon calm: animated film may ease Kids' surgery fears
Symptom relief CompletedThis trial investigates whether a double-reading animated film, watched by both children and their parents before surgery, can reduce anxiety in children aged 3 to 7. The film uses avatars to walk the child through their hospital journey, from room to operating room. Researchers …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Acupressure may ease fatigue in young cancer survivors
Symptom relief CompletedThis study tested whether young cancer survivors (ages 15-39) could learn to do acupressure on themselves to reduce fatigue. 42 people who had finished cancer treatment at least three months ago and still felt tired took part. They used a special tool and a phone app to apply pre…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could an amino acid shorten sickle cell pain crises?
Symptom relief CompletedThis phase 3 trial tests whether intravenous arginine, an amino acid, can shorten painful episodes in children with sickle cell disease. Participants aged 3 to 21 receive either arginine or a placebo alongside standard pain treatment. The study measures how quickly the crisis res…
Phase: PHASE3 • Sponsor: Claudia R. Morris • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New supplement shows promise for sickle cell sufferers in early trial
Symptom relief CompletedThis study tested a daily dietary supplement called NUV001 in 12 adults with sickle cell disease (SS type) over 120 days. The main goals were to see if it is safe and tolerable, and to measure its effects on blood health and quality of life. Researchers tracked side effects, hosp…
Phase: NA • Sponsor: LGD • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Talking therapy shows promise for MG patients with depression in tiny pilot study
Symptom relief CompletedThis study looked at whether having a tendency toward depression affects how well people with thymoma-associated myasthenia gravis (MG) respond to psychological counseling. Nineteen adults who had surgery for thymoma and MG received eight sessions of counseling based on Gestalt t…
Phase: NA • Sponsor: Ming-Hsing Chang • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could an ancient herb ease Chemo's worst side effects?
Symptom relief CompletedThis study tests whether PG2, a compound from the astragalus root, can reduce fatigue and low white blood cell counts caused by chemotherapy in women with stage II or III breast cancer. Participants receive either PG2 or a placebo alongside their standard chemotherapy. The goal i…
Phase: PHASE2 • Sponsor: PhytoHealth Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New program helps caregivers of stem cell patients cope better
Symptom relief CompletedThis study tested a support program for people caring for a loved one undergoing a stem cell transplant for blood cancer. The program included 8 online sessions over 12 weeks to teach stress management, coping skills, and communication. 17 caregivers took part, and the study chec…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could chemo at home become a reality for myeloma patients?
Symptom relief CompletedThis study explored whether multiple myeloma patients could safely administer the drug Carfilzomib at home instead of always going to the hospital. Nine patients who had already received at least one treatment cycle in the clinic were taught to give themselves the infusion on cer…
Sponsor: Thomas Lund • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New sponge stops bleeding faster after wisdom tooth extraction
Symptom relief CompletedThis study tested a new dental sponge called Colibricare (Coli-sorb®) in 124 patients having their wisdom teeth removed. The sponge was compared to a standard gauze and a commercial sponge. Researchers measured how quickly bleeding stopped, pain levels, swelling, and wound healin…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Talking away the tiredness: CBT tackles Post-Transplant fatigue
Symptom relief CompletedThis study looked at whether a type of talk therapy called cognitive-behavioral therapy (CBT) can help reduce the severe tiredness that many people feel after a stem cell transplant for blood cancer. 66 adults who had a transplant at least 6 months earlier and still had significa…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Hot water rinse during sinus surgery may stop bleeding faster
Symptom relief CompletedThis study tested whether rinsing the sinuses with hot saline (50°C) during surgery for chronic sinusitis reduces bleeding and improves the surgeon's view. 59 adults were split into three groups: hot saline, room-temperature saline, or no rinse. The goal was to see if the hot rin…
Phase: NA • Sponsor: Military Institute of Aviation Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Ancient remedy takes on chemo nerve damage
Symptom relief CompletedThis study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…
Phase: NA • Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Fencing fights fatigue: new program aims to keep blood cancer patients moving
Symptom relief CompletedThis study tested whether a fencing-based exercise program is practical for adults with leukemia or lymphoma who are receiving intensive treatment in a hospital. The goal was to reduce physical decline caused by long bed rest. Eighty patients were invited to take part, and resear…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
Exercise program shows promise for hemophilia patients
Symptom relief CompletedThis study tested whether a 6-month adapted physical activity program could improve functional capacity in people with hemophilia. Fourteen participants did exercises twice a week to improve joint mobility, strength, and balance. The main goal was to see if their walking distance…
Phase: NA • Sponsor: Istituto Ortopedico Rizzoli • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Cheap shot: Low-Cost PRP injection eases joint pain in hemophilia patients
Symptom relief CompletedThis study tested whether a low-cost version of platelet-rich plasma (PRP) injections could safely ease joint pain and swelling in people with bleeding disorders like hemophilia. Fourteen adults with joint damage received the injection and were followed for 6 months. The goal was…
Phase: NA • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Special PE program shows promise for building muscle in teens with intellectual disability
Symptom relief CompletedThis study tested a 10-week progressive adapted physical education program for 46 adolescents with mild intellectual disability. Half did the special program plus regular school activities, while the other half stuck to their usual curriculum. Researchers measured upper-body stre…
Phase: NA • Sponsor: Inonu University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can a sedative stop Post-Surgery agitation in children?
Symptom relief CompletedThis completed study tested whether giving children the drug dexmedetomidine during tonsillectomy surgery could reduce pain and agitation afterward. 85 children aged 2-10 took part. Researchers measured pain and anxiety levels after the operation to see if the drug helped compare…
Sponsor: Burak Omur • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Virtual forests lift mood: VR nature boosts depression treatment
Symptom relief CompletedThis study tested whether adding virtual reality (VR) nature experiences to standard treatment helps adults with mild to moderate depression feel better. 45 participants were split into three groups: one used a high-end VR lab setup, another used a simple self-managed VR, and a c…
Phase: NA • Sponsor: Sykehuset Innlandet HF • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can a Live-Streaming brain health program boost memory in older adults?
Symptom relief CompletedThis study tested a 12-week online program called Brain Health Together for older adults with mild cognitive decline. Participants joined live-streaming exercise and education classes, plus individual coaching, all from home. The goal was to see if the program could improve think…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Talking therapy shows promise for trauma in people with learning disabilities
Symptom relief CompletedThis study tested whether an adapted form of Narrative Exposure Therapy (NET) is acceptable and helpful for adults with mild learning disabilities who have experienced trauma. Thirteen participants completed the therapy, which involved talking through their life events in a struc…
Phase: NA • Sponsor: University of Nottingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Major study compares transplant vs. standard care for rare immune disease
Knowledge-focused CompletedThis study looked at 137 people with Chronic Granulomatous Disease (CGD), a rare immune disorder. It compared those who received a stem cell transplant with those who got standard care. The goal was to see which patients benefit most from transplant and what type of transplant wo…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Family secrets? study maps how relatives talk about genetic health risks
Knowledge-focused CompletedThis study explored how family members share health information about genetic diseases like sickle cell, diabetes, and cancer. Over 1,000 adults completed surveys or interviews about their family health history and support. The goal was to understand social and relational factors…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
PET scans may reveal hidden leukemia spots before CAR t treatment
Knowledge-focused CompletedThis pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists hunt for hidden causes of painful leg ulcers in sickle cell disease
Knowledge-focused CompletedThis completed study looked at why people with sickle cell disease develop chronic leg ulcers. Researchers collected skin swabs, blood samples, and survey data from 405 adults to explore the role of skin bacteria and environmental factors. The goal was to better understand the ca…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Small study aims to unlock secrets of rare lung disease
Knowledge-focused CompletedThis completed Phase 1 study looked at 27 people with and without pulmonary hypertension to learn more about how blood vessel problems contribute to the disease. Researchers used heart catheterization, imaging, and blood tests to find biomarkers and understand disease mechanisms.…
Phase: PHASE1 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists investigate relapse after CAR t: blood draws hold clues
Knowledge-focused CompletedThis study tracks 50 people with blood cancers who are receiving CAR T therapy. Researchers will take blood samples over time to measure immune cells and genetic changes. The goal is to find patterns that predict or explain why the cancer comes back. This is an observational stud…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Can we predict dangerous blood clots in lymphoma patients? a major study aims to find out
Knowledge-focused CompletedThis study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are…
Sponsor: Fondazione IRCCS San Gerardo dei Tintori • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists map protein patterns in lymphoma to unlock disease secrets
Knowledge-focused CompletedThis completed study analyzed leftover tissue samples from 130 people with lymphoma or related conditions. Researchers measured levels of histone and other proteins to find patterns linked to different lymphoma types. The goal was to better understand the biology of these cancers…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New blood test could help patients who Don't respond to platelet transfusions
Knowledge-focused CompletedThis study looked at 68 people with low platelet counts who had become resistant to platelet transfusions due to HLA antibodies. Researchers tested a new lab method (C1q binding) on stored blood samples to see if it could better predict whether a transfusion would work compared t…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Lymphoma drug safety under the microscope in 1,000-Patient study
Knowledge-focused CompletedThis study follows 1,000 people with CD30-positive lymphoma who are already receiving or about to receive brentuximab vedotin as part of their normal care. Researchers will track side effects and how the drug is used in everyday practice, without giving any new treatment. The goa…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New document helps young adults voice End-of-Life wishes
Knowledge-focused CompletedThis study tested a document called Voicing My CHOiCES, designed to help young adults (ages 18-39) with serious illnesses like cancer or HIV discuss their care preferences. Participants filled out questionnaires about anxiety, social support, and communication, then reviewed the …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can genes predict liver damage from childhood cancer drugs?
Knowledge-focused CompletedThis study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists hunt for hidden genetic causes of rare bleeding disorder
Knowledge-focused CompletedThis study investigates inherited thrombocytopenias, rare conditions where low platelet counts cause bleeding problems. About half of patients have an unknown genetic cause. Researchers aim to identify new disease genes and build a lab-grown bone marrow model to test how well dru…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Wearable sensors monitor ALS progression in new study
Knowledge-focused CompletedThis study tests whether wearable sensors and digital home tasks can track changes in movement, speech, and falls in people with ALS. About 20 participants will wear neck and wrist sensors and complete speech and handwriting tests over 48 weeks. The goal is to see if these digita…
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World data reveals how bosutinib fights leukemia outside clinical trials
Knowledge-focused CompletedThis study looks back at medical records from a single hospital in Scotland to see how well the drug bosutinib works and how safe it is for people with chronic myeloid leukemia (CML) in everyday practice. Researchers will track blood cell counts, genetic responses, and side effec…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists probe blood changes during sickle cell pain crises
Knowledge-focused CompletedThis study looked at what happens in the blood of people with sickle cell disease during painful attacks. Researchers compared blood samples taken during a pain crisis to samples taken when participants were feeling well. The goal was to learn more about the role of inflammation …
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Kidney study reveals how opemalirsen behaves in the body
Knowledge-focused CompletedThis completed study looked at how the drug opemalirsen (AZD2373) is processed in people with different levels of kidney function. Researchers gave a single injection to 35 adults, some with kidney impairment and some with healthy kidneys. The goal was to compare drug levels and …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Real-World study tracks Poteligeo's impact on rare skin cancer symptoms
Knowledge-focused CompletedThis completed observational study followed 73 adults with mycosis fungoides or Sézary syndrome who were starting treatment with Poteligeo. Researchers tracked changes in symptoms like itching, skin pain, and fatigue, as well as quality of life for patients and their caregivers. …
Sponsor: Kyowa Kirin Pharmaceutical Development Ltd • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Liver function may change how tirabrutinib acts in the body
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug tirabrutinib is processed in people with mild, moderate, or severe liver impairment compared to healthy volunteers. Forty participants took a single oral dose, and researchers measured drug levels and safety. The goal was to und…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Sickle cell patients checked for hidden lung danger
Knowledge-focused CompletedThis study measured how common pulmonary hypertension (high blood pressure in the lungs) is in adults with sickle cell anemia. Nearly 1,000 participants had heart ultrasounds and blood tests, then were contacted by phone for up to 3 years to track their health. The goal was to un…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New hemophilia drug may last longer, reducing need for frequent shots
Knowledge-focused CompletedThis study tested a new drug called efanesoctocog alfa in 24 adults with severe hemophilia A. Researchers compared how long it stays in the body versus two existing drugs. Participants received one dose of their usual drug, then later one dose of the new drug, with blood samples …
Phase: PHASE1 • Sponsor: Swedish Orphan Biovitrum • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New algorithm aims to speed up diagnosis of mysterious high white blood cell counts
Knowledge-focused CompletedThis study tested a decision algorithm to help doctors diagnose the cause of eosinophilia (high levels of a type of white blood cell). The algorithm guides which tests to do and in what order. Researchers enrolled 53 patients and measured how many followed the algorithm correctly…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Gut bacteria may hold key to chemo side effects
Knowledge-focused CompletedThis study looked at how chemotherapy affects the gut microbiome in 40 people with non-Hodgkin's lymphoma. Researchers collected stool samples to analyze changes in gut bacteria after treatment. The goal was to better understand why chemotherapy causes digestive problems like dia…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Stem cell transplant leaves many women with hidden gynecological issues
Knowledge-focused CompletedThis study looked at 51 women who had a stem cell transplant for acute leukemia as adults. Researchers wanted to find out how many had gynecological problems like early menopause, vaginal graft-versus-host disease, or cervical issues two years after transplant. They also checked …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Real-Time tissue test may help surgeons avoid unnecessary neck dissections in thyroid cancer
Knowledge-focused CompletedThis pilot study tested whether a rapid lab test called frozen section analysis, done during thyroid surgery, can help surgeons decide how many lymph nodes to remove from the neck. The study included 66 adults with low-risk thyroid cancer and no signs of spread before surgery. Th…
Sponsor: Eleonora Lori, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could a pneumonia drug boost leukemia treatment? small trial explores safety and dosing
Knowledge-focused CompletedThis early-phase trial tested whether adding atovaquone (a drug usually used to prevent pneumonia) to standard chemotherapy is safe and reaches effective levels in the blood. It involved 26 children and young adults (ages 1 month to 21 years) newly diagnosed with acute myeloid le…
Phase: EARLY_PHASE1 • Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Dust and crops: scientists hunt for Pesticide-Leukemia link in kids
Knowledge-focused CompletedThis study looked at 629 children in California to see if exposure to pesticides at home or from nearby farms is linked to childhood leukemia. Researchers collected dust from carpets and vacuum cleaners and mapped crops near homes. The goal was to measure chemical levels and see …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Farmers' pesticide use linked to blood cancer precursors
Knowledge-focused CompletedThis study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists track rare muscle disease to unlock its secrets
Knowledge-focused CompletedThis study followed 78 people with GNE myopathy, a rare genetic disease that causes progressive muscle weakness starting in young adulthood. Researchers collected medical history, blood samples, and muscle function tests over up to two years to understand how the disease progress…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Researchers review CAR T-Cell results in kids with B-ALL
Knowledge-focused CompletedThis study looked back at the medical records of 57 children and young adults (under 25) who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). The goal was to understand how well the treatment worked and what side effects occurred, especially in those w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Are sickle cell patients becoming addicted to pain relief? new study investigates
Knowledge-focused CompletedThis completed observational study looked at how often young people with sickle cell disease (under 26) in France develop problematic use of painkillers and a gas mixture called EMONO. Researchers interviewed over 1,000 patients by phone to check for signs of addiction or depende…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
No treatment, just observation: large study looks at PNH blood cells
Knowledge-focused CompletedThis completed study looked at red and white blood cells in people with a rare blood disorder called PNH who also have bone marrow failure. Over 5,500 participants aged 10 and older with aplastic anemia or related conditions provided blood samples. The goal was simply to learn mo…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Real-World use of clotting factor in iraqi haemophilia patients examined
Knowledge-focused CompletedThis completed study observed how 329 Iraqi male patients with haemophilia A used turoctocog alfa (a clotting factor) in their daily care. Researchers reviewed medical records to see how the drug was given and how many bleeding episodes occurred. The goal was to describe real-wor…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to unlock the secrets of Children's rare blood diseases
Knowledge-focused CompletedThis study follows children in France diagnosed with severe autoimmune cytopenia—conditions where the immune system attacks blood cells. Researchers will track their health over time to see who achieves remission and what factors influence their recovery. The goal is to better un…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can scans and blood predict CAR T-Cell success?
Knowledge-focused CompletedThis pilot study looked at whether special scans (18FDG PET-CT) and blood tests could help predict how well CAR T-cell therapy works for people with hard-to-treat non-Hodgkin's lymphoma. Twenty patients were followed for up to a year after treatment. The goal was to see if these …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple blood test predict who will get chronic ITP?
Knowledge-focused CompletedThis completed study looked at blood samples from 70 children and adults newly diagnosed with immune thrombocytopenic purpura (ITP), a condition that causes easy bruising and bleeding. Researchers wanted to see if certain immune and blood markers could predict whether the disease…
Phase: PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to uncover hidden hormone failure in ICU patients
Knowledge-focused CompletedThis study looks at how the adrenal glands work in people who are critically ill, such as those with sepsis. Adrenal insufficiency may affect up to 77% of ICU patients, but current tests are not reliable. Researchers will measure hormone levels in 225 participants, including heal…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New guide aims to help myeloma patients stick to their pill regimen
Knowledge-focused CompletedThis study aims to develop a standardized reference guide for pharmacists to use during initial consultations with multiple myeloma patients starting oral chemotherapy. The goal is to provide clear, consistent information that helps patients understand and follow their treatment …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for allergy genes in massive screening study
Knowledge-focused CompletedThis study screened up to 1,000 people with severe allergic conditions—like anaphylaxis, eczema, and asthma—along with their relatives to find genetic causes. Researchers collected blood samples and medical history to link specific gene mutations to these diseases. No treatment w…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Timing your meals could make this hemophilia drug work better
Knowledge-focused CompletedThis study tests a new medicine called Inno8 for hemophilia A. Researchers want to see how eating and drinking before and after taking the pill changes how much medicine gets into the blood. 80 healthy men aged 18-45 will take one dose after fasting, then wait different times bef…
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study Fine-Tunes malaria drug dosing for kids
Knowledge-focused CompletedThis completed study looked at how the malaria drug artesunate works in 90 Ugandan children aged 6 months to 14 years with severe malaria. Researchers measured drug levels in the blood and tracked vital signs like temperature and blood pressure to see how the body responds. The g…
Phase: PHASE4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
ER wait after admission costs millions, study finds
Knowledge-focused CompletedThis study looked at over 30,000 adults admitted to hospitals in Maryland to understand why some patients wait in the emergency room even after being admitted (called boarding). Researchers wanted to find out what patient traits lead to longer waits, how boarding increases health…
Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Malaria's next threat: drug-resistant parasites spread even after treatment
Knowledge-focused CompletedThis study looked at whether malaria parasites that are resistant to artemisinin drugs spread more easily after standard treatment. Researchers treated 160 people in Uganda who had malaria with either artemether-lumefantrine or dihydroartemisinin-piperaquine. They then used mosqu…
Phase: PHASE4 • Sponsor: Infectious Diseases Research Collaboration, Uganda • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study examines artery complications in child liver transplants
Knowledge-focused CompletedThis study looked at 583 children who had liver transplants and later developed narrowing or blockage of the liver artery. Researchers wanted to find out how common these problems are and what treatments work best. The goal is to improve care and outcomes for future patients.
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Transplant vs. standard care: which protects sickle cell Kids' brains better Long-Term?
Knowledge-focused CompletedThis study followed 67 children with sickle cell disease who had a high risk of stroke. Researchers compared those who received a bone marrow transplant to those who got standard care, checking brain scans and thinking skills 9-10 years later. The goal was to see which approach b…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI-Powered imaging could revolutionize anemia diagnosis
Knowledge-focused CompletedThis study tested a new way to analyze red blood cells in people with anemia using flow imaging and artificial intelligence. Instead of the usual method of spreading blood on a slide and staining it, the researchers used a machine that takes pictures of cells flowing in liquid. T…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could natural immune cells help fight leukemia drug resistance?
Knowledge-focused CompletedThis completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can telemedicine help kids with sickle cell disease get better care?
Knowledge-focused CompletedThis study looked at whether two different telemedicine models could help children with sickle cell disease living in medically underserved areas get better care. Researchers tested the models with 24 families and measured things like appointment attendance, lab work, and satisfa…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Japanese study tracks Esperoct's Real-World safety over two years
Knowledge-focused CompletedThis study watched 23 people with hemophilia A who were already using Esperoct as part of their normal care. Researchers tracked side effects and how well the medicine worked over about two years. The goal was to confirm the drug's safety and effectiveness in everyday use, not to…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New eDiary helps track sickle cell pain and fatigue
Knowledge-focused CompletedThis study tested an electronic diary for adults with sickle cell disease to track daily symptoms like pain, tiredness, and ability to do usual activities. About 98 participants used the diary for 6 months, and researchers compared those on disease-modifying treatment to those no…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
NIH study aims to unlock secrets of lung mucus diseases
Knowledge-focused CompletedThis completed study looked at people with genetic conditions that affect how the lungs clear mucus, such as cystic fibrosis and primary ciliary dyskinesia. Researchers examined 87 participants, including healthy volunteers, to understand why these patients get repeated lung infe…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Which kidney test works best for sickle cell patients? study aims to find out
Knowledge-focused CompletedThis study looked at 70 adults with sickle cell disease to see which lab test—cystatin C or creatinine—better measures kidney function. Participants gave blood and urine samples and had a special dye test to check how well their kidneys work. The goal is to help doctors catch kid…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Weighty issue: does obesity block iron supplements?
Knowledge-focused CompletedThis study examined the link between obesity and iron deficiency anemia in 165 nonpregnant Indonesian women aged 19-29. Participants took daily iron-folic acid supplements for 90 days. Researchers compared iron levels between overweight/obese and normal-weight women to see if wei…
Phase: NA • Sponsor: Griffith University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists hunt for clot clues in sickle cell blood
Knowledge-focused CompletedThis study examined blood samples from 119 adults with sickle cell disease, sickle cell trait, or no condition to understand why some develop dangerous blood clots. Participants gave blood and had health check-ins over two years. The goal was to find biomarkers that could lead to…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Survey reveals Pandemic's toll on sickle cell patients
Knowledge-focused CompletedThis study surveyed 186 adults with sickle cell disease in the U.S. to learn how the COVID-19 pandemic impacted their stress, anxiety, pain, and healthcare use. Participants completed online questionnaires about their medical history, mental health, and experiences during the pan…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Could a common virus be behind rashes in blood cancer patients?
Knowledge-focused CompletedThis study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Hidden deficiencies in black college athletes under the microscope
Knowledge-focused CompletedThis pilot study investigates how common low energy availability, iron deficiency, and low vitamin D levels are among Black collegiate athletes. Participants who are found to have low iron or vitamin D will receive daily supplements for 12 weeks. The goal is to better understand …
Phase: NA • Sponsor: Morehouse School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Gene test spots hidden leukemia in kids
Knowledge-focused CompletedThis study looked at 148 children with T-cell acute lymphoblastic leukemia to see if a high-tech gene test could find tiny amounts of cancer left after treatment. Researchers used next-generation sequencing to check for specific gene changes in immune cells. They then compared th…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Scientists hunt for hidden genes behind common bleeding disorder
Knowledge-focused CompletedThis study examined the DNA of 254 people to find genetic changes that might explain why some individuals have mildly low levels of von Willebrand factor, a protein important for blood clotting. Researchers used whole-exome sequencing to look for variants in known and new genes. …
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Early safety check for new sepsis clotting drug
Knowledge-focused CompletedThis early-stage study tested a new drug called BAY 3389934 in 16 healthy Japanese adults to see if it is safe and how the body handles it. The drug is being developed to treat a serious blood clotting condition that can happen with severe infections (sepsis). Participants receiv…
Phase: PHASE1 • Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Plant-Derived heme iron: a new way to fight iron deficiency?
Knowledge-focused CompletedThis study looked at how well iron-deficient women absorb iron from two plant-based sources—iron chlorophyllin and soy hemoglobin—compared to standard ferrous sulfate and animal-based heme iron. Forty-five women with low iron stores but not anemic took each type of iron in water …
Phase: NA • Sponsor: ETH Zurich • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Which drug works better for stem cell collection? study compares zarzio and granocyte
Knowledge-focused CompletedThis completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Instacart and nutrition calls may ease food insecurity for cancer survivors
Knowledge-focused CompletedThis study tested whether providing grocery delivery (via Instacart) and weekly nutrition coaching calls helps cancer survivors who struggle to afford healthy food. Forty survivors who had finished active cancer treatment took part. The goal was to see if this support was practic…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Study probes link between transfusions and gut trouble in preterm infants
Knowledge-focused CompletedThis completed study looked at 324 extremely low birth weight preterm infants (≤1250 grams) to see how anemia and red blood cell transfusions affect oxygen levels in their digestive tract. Researchers used a non-invasive device to measure tissue oxygen and collected blood, urine,…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Bone loss in hemophilia: new study measures the hidden risk
Knowledge-focused CompletedThis study looked at bone density in 448 men with hemophilia and healthy volunteers to see how common bone loss is. Participants had a bone density scan and some gave blood samples. The goal was to understand if hemophilia itself, not just lack of activity, leads to weaker bones.
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
PET scans may sharpen staging for rare lymphoma
Knowledge-focused CompletedThis study examined whether PET scans can help doctors better stage mantle cell lymphoma and predict how patients will fare, compared to standard CT scans and bone marrow biopsies. Researchers analyzed data from 200 patients who had already completed a clinical trial. The goal wa…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
633 PMBCL patients studied: key insights on refractory disease and survival
Knowledge-focused CompletedThis study looked back at 633 people with primary mediastinal large B-cell lymphoma (PMBCL) treated in Italy between 2007 and 2019. Researchers collected data on how well treatments worked, how many patients had disease that didn't respond or came back early, and survival rates. …
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
C-Section pain relief: does ketorolac raise bleeding risk?
Knowledge-focused CompletedThis study looked at how ketorolac, a non-steroidal anti-inflammatory drug (NSAID) used for pain after cesarean delivery, affects platelet function and blood clotting. Researchers measured clotting in 40 women undergoing scheduled C-sections using special blood tests. The goal wa…
Phase: PHASE4 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Eye disease biobank seeks clues to uveitis
Knowledge-focused CompletedThis study collected blood, saliva, and eye fluid samples from 343 people with uveitis, an inflammatory eye disease that can cause vision loss. Researchers aimed to learn which genes and other factors might lead to the disease and affect treatment response. Participants were foll…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Hidden danger: why some patients can't shake COVID-19
Knowledge-focused CompletedThis study tracked 204 patients with blood cancers or those on certain immune-suppressing treatments to see how often COVID-19 infection persists for 21 days or more. Researchers also looked for factors that make a long infection more likely. The goal was to better understand who…
Sponsor: Maddalena Giannella • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Which drug combo works best for returning myeloma?
Knowledge-focused CompletedThis study looked back at medical records of 100 adults with multiple myeloma that had returned after initial treatment. Researchers compared how long patients stayed cancer-free on four different three-drug combinations. The goal was to see which combination worked best in real-…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Heart risks under the microscope: lenalidomide safety study in myeloma
Knowledge-focused CompletedThis study followed over 900 newly diagnosed multiple myeloma patients who were not eligible for a stem cell transplant. Researchers compared heart-related side effects between those treated with lenalidomide (Revlimid) and those receiving other treatments. The goal was to better…
Sponsor: Celgene • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Study reveals vaccine response in Immune-Compromised patients
Knowledge-focused CompletedThis study looked at how people with autoimmune diseases like multiple sclerosis or blistering skin conditions respond to COVID-19 vaccines while on B-cell depleting therapies. Researchers measured antibody levels and T-cell activity over time to understand vaccine effectiveness …
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Scientists dig into DNA to unravel blood clot mysteries in rare disorder
Knowledge-focused CompletedThis study looks at people with a rare inherited condition called dysfibrinogenemia, which affects how blood clots form. Researchers collected blood samples from 70 patients to analyze clot structure and search for genetic variations that might explain why some patients bleed whi…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New study tracks immune cell function after stem cell transplants to personalize care
Knowledge-focused CompletedThis completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
What It's like to live with Low-Risk MDS: patients share their stories
Knowledge-focused CompletedThis completed study in Japan looked at how low-risk myelodysplastic syndrome (MDS) or unexplained anemia affects patients' daily lives. Researchers used questionnaires and interviews with 56 participants to understand symptoms, quality of life, and unmet needs. The goal was to c…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Scientists probe the root cause of a rare bone marrow disease
Knowledge-focused CompletedThis completed study looked at blood vessel cells from 30 people with primary myelofibrosis, a rare bone marrow disorder. Researchers wanted to see if these cells act like stem cells that could be the origin of the disease. By growing the cells in the lab, they aimed to understan…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Scientists track lifespan of transfused blood in sickle cell kids
Knowledge-focused CompletedThis study looked at how long donor red blood cells survive in children with sickle cell disease who get regular blood transfusions. Researchers labeled a small part of the transfused blood with a harmless marker and tracked it over time. The goal was to better understand why som…
Phase: PHASE1 • Sponsor: Marianne Yee • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Rare bleeding disorder study seeks to unlock antibody mystery
Knowledge-focused CompletedThis study looked at 28 people with Glanzmann thrombasthenia, a rare bleeding disorder, to understand why some develop harmful antibodies after blood transfusions or pregnancy. Researchers checked for antibodies every six months and after each transfusion over 18 months. The goal…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Tiny camera may spot hidden bleeding in rare blood disorder
Knowledge-focused CompletedThis study looked at whether using a video capsule endoscopy (a small camera pill) along with standard scopes can better find the source of gut bleeding in people with von Willebrand disease. Researchers reviewed records of 50 patients who had gut bleeding between 2015 and 2017. …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Small study checks kidney and race impact on transplant drug
Knowledge-focused CompletedThis study looked at how kidney function and race/ethnicity affect the drug treosulfan in 20 patients with AML or MDS getting a stem cell transplant. The goal was to find safe doses for those with kidney problems. It was a small, early-phase study that did not test a new treatmen…
Phase: PHASE1 • Sponsor: medac GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists map hidden germs in kids with cancer
Knowledge-focused CompletedThis study looked at the tiny organisms (bacteria and fungi) living in the mouth and nose of children with leukemia or those getting a bone marrow transplant. Researchers wanted to see how these germ communities change during chemotherapy. The goal was to learn more, not to test …
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Blood cancer enzyme deficiency explored in new study
Knowledge-focused CompletedThis study looked at how often people with certain blood cancers or related conditions have an acquired deficiency of an enzyme called pyruvate kinase, which can cause anemia. Researchers took a single blood sample from 18 participants to measure enzyme activity and check for rel…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New study reveals how well COVID vaccines protect myeloma patients
Knowledge-focused CompletedThis study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…
Sponsor: ASH Research Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New program aims to break down barriers to cancer trial participation
Knowledge-focused CompletedThis pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
C-Section bleeding study: does tranexamic acid help clotting?
Knowledge-focused CompletedThis study examined how the drug tranexamic acid (TXA) affects blood clotting in women having planned C-sections. Researchers measured clot breakdown times in 34 participants to see if TXA could help prevent heavy bleeding after delivery. The goal was to better understand how TXA…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Large study checks safety of rituximab pfizer in lymphoma patients
Knowledge-focused CompletedThis study looked at medical records from over 2,700 people in Japan with a type of lymphoma (B-cell non-Hodgkin's lymphoma) who were treated with Rituximab Pfizer. The goal was to see how often infections and other side effects happened, and to compare these results with those f…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Blood cell study may personalize asthma and sinusitis treatment
Knowledge-focused CompletedThis study looked at different types of immune cells (eosinophils) in the blood of people with asthma, chronic sinusitis with nasal polyps, or both, compared to healthy volunteers. The goal was to find patterns that could help doctors choose the best targeted therapy for each pat…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Lupus clue: can a heart drug reveal hidden disease markers?
Knowledge-focused CompletedThis small pilot study looked at whether clopidogrel, a drug that stops blood clots, could lower a substance called sCD40L in people with lupus. Lupus is an autoimmune disease where the body attacks itself. The study involved 18 adults with lupus and measured sCD40L levels in the…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Mold infection risk in kids with leukemia: a 14-year review
Knowledge-focused CompletedThis study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…
Sponsor: University of Southern Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Scientists hunt for clues to deadly sepsis complication in european patients
Knowledge-focused CompletedThis study examined 150 adults with sepsis in the ICU to find blood markers that signal when the condition turns into a dangerous clotting problem called DIC. Researchers collected blood samples and hospital data over up to 56 days, but did not test any new treatments. The goal i…
Phase: NA • Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Healthy men swallow radioactive drug to track its path
Knowledge-focused CompletedThis study gave 6 healthy men a single dose of a radioactive form of the experimental drug DZD8586. The goal was to see how the drug moves through the body, how it is broken down, and how it leaves the body in urine and stool. This information helps researchers understand the dru…
Phase: PHASE1 • Sponsor: Dizal Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New breathing tube technique shows promise for kids in surgery
Knowledge-focused CompletedThis study looked at a different way to help children breathe during surgery. Instead of placing the breathing tube all the way into the windpipe, doctors placed it just above the vocal cords. The goal was to see if this method is easy, safe, and works well. The study included 85…
Sponsor: American University of Beirut Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Could your diet trigger lupus? new study investigates
Knowledge-focused CompletedThis study measured phytoestrogens (plant-based compounds) in the blood and urine of 63 premenopausal women with active lupus, other autoimmune diseases, or no disease. Researchers also asked about diet and measured estradiol levels. The goal was to see if these dietary compounds…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New tool helps older leukemia patients and doctors talk better
Knowledge-focused CompletedThis study tested a tool called UR-GOAL to help older patients with acute myeloid leukemia (AML), their caregivers, and their doctors communicate better and make decisions together. It involved 161 participants aged 60 and older. The goal was to see if the tool improved shared de…
Phase: NA • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Experimental clotting agent VMX-C001 tested with common blood thinners
Knowledge-focused CompletedThis early study tested an experimental drug called VMX-C001 in 16 healthy adults to see how it affects blood clotting when taken with common blood thinners like rivaroxaban and enoxaparin. The goal was to measure changes in various clotting tests, not to treat any disease. Becau…
Phase: PHASE1 • Sponsor: VarmX B.V. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Liver study tests how drug AZD2693 behaves in impaired patients
Knowledge-focused CompletedThis study looked at how a single dose of the drug AZD2693 moves through the body in people with liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood to understand safety and processing differences. A total of 35 adults took part. The goa…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New surgical clip tool tested in 161 patients
Knowledge-focused CompletedThis study looked at a new device called AE05ML that helps surgeons place clips on blood vessels and other tissues during keyhole surgery. The goal was to see if the device is safe and works well. A total of 161 adults took part in the study.
Sponsor: Teleflex • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New study aims to predict dangerous bleeding during weight-loss surgery
Knowledge-focused CompletedThis study looked back at the records of over 9,000 people who had weight-loss (bariatric) surgery. The goal was to find factors that might predict bleeding during or within 30 days after surgery. By identifying these risk factors, doctors hope to create a score that can help pre…
Sponsor: Assuta Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
What do patients really think? small study asks multiple myeloma survivors about their treatment journey
Knowledge-focused CompletedThis study interviewed 9 people with multiple myeloma who had received at least 5 different treatments. The goal was to learn about their experiences and what factors are most important to them when deciding on a treatment. No new drugs or therapies were tested; instead, the stud…
Sponsor: The Christie NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New training aims to help doctors catch child abuse earlier
Knowledge-focused CompletedThis study looked at whether a new educational program helps doctors-in-training better recognize and respond to child maltreatment. 84 medical residents from Canadian universities took part. The program was delivered either in a group with a leader or on their own. The goal was …
Phase: NA • Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
IPad brain games tested in young cancer survivors
Knowledge-focused CompletedThis study looked at whether children and teens who had a stem cell transplant for leukemia could use an iPad-based brain-training program. The main goal was to see if the program was practical and if kids would stick with it. Only 17 participants were enrolled, and the study foc…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Magnesium levels linked to clotting risk in sepsis
Knowledge-focused CompletedThis study looked at 150 adults with sepsis in the ICU to see if low magnesium levels are connected to blood clotting problems. Researchers measured magnesium and clotting markers at admission and tracked outcomes like DIC and survival. The goal was to understand if magnesium cou…
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New study maps the path from smoldering to active myeloma
Knowledge-focused CompletedThis study reviewed medical records of 431 people with smoldering multiple myeloma (SMM), a pre-cancerous condition, to see how the disease progresses over time. Researchers looked at which patients are at higher risk of developing active multiple myeloma and what treatments they…
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Ultrasound breakthrough: can it spot cancer in lymph nodes?
Knowledge-focused CompletedThis study tested a new ultrasound technique to see the smallest blood vessels in lymph nodes on the neck. Researchers wanted to know if this method could tell the difference between healthy and cancerous lymph nodes. Twenty adults with head and neck cancer, lymphoma, or healthy …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Anemia duration may predict ventilator days in ICU patients
Knowledge-focused CompletedThis study examined 236 adults in a surgical intensive care unit who needed a breathing machine for more than 4 days. Researchers wanted to see if the length of time a patient had anemia (low red blood cells) was linked to how long they stayed on the ventilator. The goal was to b…
Sponsor: Mahidol University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Leukemia Patients' hidden threat: fungal infections under microscope
Knowledge-focused CompletedThis study observed 150 adults with a specific type of leukemia (Ph-negative ALL) to see how many developed serious fungal infections during their first weeks of chemotherapy. Researchers tracked infection rates and deaths linked to these infections. The goal was to better unders…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Antibiotic side effects under the microscope in bone infection study
Knowledge-focused CompletedThis completed study followed 73 adults with bone or joint infections who needed antibiotics for at least 6 weeks. Researchers tracked how often side effects occurred, how severe they were, and whether they affected quality of life. The goal was to understand why some patients st…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists probe the hidden types of severe childhood asthma
Knowledge-focused CompletedThis completed study looked at 54 children with severe asthma to better understand the different biological features (endotypes) of the disease. Researchers collected blood, saliva, and nasal samples, along with lung samples from bronchoscopies, to analyze immune cells, metabolis…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Exercise may boost heart fitness in hodgkin survivors
Knowledge-focused CompletedThis study looked at whether exercise training can improve physical capacity and heart function in adults who survived Hodgkin lymphoma after chemotherapy and chest radiation. Forty survivors took part in fitness tests and heart monitoring. The goal was to see if exercise could r…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Which iron pill works best? small study tests natural vs. standard supplements
Knowledge-focused CompletedThis completed study looked at how well healthy pre-menopausal women with low iron stores absorb iron from two different supplements: Spatone (a natural iron-rich water) and ferrous sulphate (a standard iron pill). Fourteen women took three different doses (5, 10, and 15 mg) of e…
Phase: NA • Sponsor: King's College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New Long-Acting malaria shot tested in humans for first time
Knowledge-focused CompletedThis study tests a single injection of a new long-acting malaria drug called MMV371 in 32 healthy adults. The main goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored for about 12 weeks for side effects…
Phase: PHASE1 • Sponsor: Medicines for Malaria Venture • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Lower platelet transfusion threshold safe for central line placement, study suggests
Knowledge-focused CompletedThis study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…
Sponsor: Thomas Kander • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a simple ultrasound spot hidden liver danger in immune disorder patients?
Knowledge-focused CompletedThis study looked at whether ultrasound and stiffness measurements of the liver and spleen can predict a serious condition called portal hypertension in people with common variable immunodeficiency (CVID). Researchers examined 250 CVID patients during routine visits, using non-in…
Sponsor: University Hospital Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New study tests simple ways to track muscle loss in kids with cancer
Knowledge-focused CompletedThis study looked at whether it's possible to measure muscle mass and physical function in children (ages 8-21) with newly diagnosed solid tumors or lymphoma during cancer treatment. Researchers used simple tests like a 6-minute walk and a special drink to measure muscle, along w…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Scientists decode cancer genes to personalize treatment
Knowledge-focused CompletedThis completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New drug EP395 tested in humans for first time
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of a new drug called EP395 in 78 healthy adults aged 18-65. Participants received either EP395 or a placebo capsule, and researchers monitored side effects, vital signs, and hearing. The goal was to find a safe dose range …
Phase: PHASE1 • Sponsor: EpiEndo Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Sickle cell drug safety in pregnancy: small study completed
Knowledge-focused CompletedThis completed study monitored pregnancy and infant outcomes in 13 women with sickle cell disease who were treated with the drug crizanlizumab (Adakveo) during pregnancy or shortly before. The goal was to track rates of fetal loss and birth defects. Because it was a small observa…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Can a computer program help doctors decode clotting tests?
Knowledge-focused CompletedThis study tested whether a new software program helps doctors more accurately interpret ROTEM blood clotting tests. Twenty-six doctors and residents from the University of Utah took part. Researchers compared their answers before and after using the software to see if it improve…
Phase: NA • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
VR rollercoasters vs. beach meditations: which changes your blood more?
Knowledge-focused CompletedThis study looked at how watching relaxing or stressful virtual reality (VR) content changes stress-related substances in the blood of 30 healthy adults. Participants watched a beach meditation or a rollercoaster ride for about 5 minutes, and blood was taken before and after. The…
Phase: NA • Sponsor: Van Creveldkliniek • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Personalized mutation tracking could spot relapse sooner in bone marrow cancer patients
Knowledge-focused CompletedThis study looked at 308 people with myelodysplastic syndromes (MDS) who had a stem cell transplant. Researchers identified each patient's unique genetic mutations and then monitored those mutations in blood and bone marrow samples after transplant. The goal was to see if rising …
Sponsor: Nordic MDS Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC